

CITATION REPORT

List of articles citing

The classification of glomerulonephritis in systemic lupus erythematosus revisited

DOI: 10.1111/j.1523-1755.2004.00443.x
Kidney International, 2004, 65, 521-30.

Source: <https://exaly.com/paper-pdf/36778960/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1100	The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. <i>Kidney International</i> , 2004 , 66, 2382-8	9.9	114
1099	Mycophenolate therapy of SLE membranous nephropathy. <i>Kidney International</i> , 2004 , 66, 2411-5	9.9	57
1098	New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences?. 2004 , 44, 1050-9		79
1097	Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. 2004 , 50, 3211-20		157
1096	Review of ACR renal criteria in systemic lupus erythematosus. 2004 , 13, 857-60		63
1095	A Revised Classification of Lupus Nephritis: In with the New. 2004 , 11, 277-278		1
1094	Lupus vasculopathy combined with renal infarction: unusual manifestation of lupus nephritis. 2005 , 44, 1185-90		5
1093	The role of kidney biopsy in the management of lupus nephritis. 2005 , 4, 197-204		
1092	The role of kidney biopsy in the management of lupus nephritis. 2005 , 14, 1-8		23
1091	[Renal manifestations of rheumatic diseases]. 2005 , 64, 18-25		2
1090	[Synovialitis score: histopathological grading system for chronic rheumatic and non-rheumatic synovialitis]. 2005 , 64, 334-42		22
1089	HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases. <i>Kidney International</i> , 2005 , 67, 1381-90	9.9	105
1088	Prediction of urinary protein markers in lupus nephritis. <i>Kidney International</i> , 2005 , 68, 2588-92	9.9	59
1087	Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease. <i>Kidney International</i> , 2005 , 68, 2621-8 ^{9.9}		72
1086	Podocyte involvement in human immune crescentic glomerulonephritis. <i>Kidney International</i> , 2005 , 68, 1109-1119	9.9	39
1085	SLE and rapidly progressive glomerulonephritis. 2005 , 45, 950-5		16
1084	Development of lupus nephritis in a patient with human T-cell lymphotropic virus type I-associated myelopathy. 2005 , 46, e25-9		2

- 1083 Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children. **2005**, 20, 1500-3 8
- 1082 Membranous lupus nephritis. **2005**, 14, 65-71 57
- 1081 Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. **2005**, 15, 28-32 15
- 1080 Case records of the Massachusetts General Hospital. Case 38-2005. A 29-year-old pregnant woman with the nephrotic syndrome and hypertension. **2005**, 353, 2590-600 16
- 1079 Pathology of lupus nephritis. **2005**, 14, 31-8 36
- 1078 Signes cliniques et biologiques des néphropathies glomérulaires. **2005**, 2, 12-30
- 1077 Lupus eritematoso sistémico. **2005**, 38, 1-24
- 1076 Small vessel vasculitis. **2005**, 14, 335-46 19
- 1075 Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis. **2005**, 65, 2429-36 4
- 1074 Lupus fythématique systématique. **2005**, 2, 1-32 5
- 1073 Poor renal outcome of antineutrophil cytoplasmic antibody negative Pauci-immune glomerulonephritis in Taiwanese. **2006**, 105, 804-12 28
- 1072 ???3?????. **2006**, 19, 70-77
- 1071 [A case of thrombotic thrombocytopenic purpura with systemic lupus erythematosus]. **2006**, 29, 342-7 4
- 1070 Lupus fythématique systématique. **2006**, 1, 1-21
- 1069 Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study. **2006**, 30, 1030-5 77
- 1068 Messenger RNA expression of RANTES in the urinary sediment of patients with lupus nephritis. **2006**, 11, 219-25 25
- 1067 Synovitis score: discrimination between chronic low-grade and high-grade synovitis. **2006**, 49, 358-64 342
- 1066 Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. **2006**, 119, 296-305 152

1065	Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. <i>Kidney International</i> , 2006 , 70, 732-42	9.9	167
1064	Update on the treatment of lupus nephritis. <i>Kidney International</i> , 2006 , 70, 1403-12	9.9	83
1063	Lupus nephropathy and cardiopulmonary and hepatic dysfunctions in a child. 2006 , 21, 1318-22		2
1062	Systemischer Lupus erythematoses im Kindes- und Jugendalter. 2006 , 154, 919-929		2
1061	Vasculitis associated with connective tissue disorders. 2006 , 8, 312-6		20
1060	A 57-year-old woman with recently diagnosed SLE, proteinuria, and microhematuria. 2006 , 48, 1004-8		2
1059	Alteration of the spontaneous systemic autoimmune disease in (NZB x NZW)F1 mice by treatment with thimerosal (ethyl mercury). 2006 , 214, 43-54		24
1058	Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. 2006 , 54, 1568-72		47
1057	Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. 2006 , 54, 2577-84		185
1056	Cappuccino mutation in an autoimmune-prone strain of mice suggests a role of platelet function in the progression of immune complex crescentic glomerulonephritis. 2006 , 54, 2934-43		6
1055	Lack of association of antibodies to ribosomal P proteins with lupus membranous glomerulonephritis: comment on the article by Do Nascimento et al. 2006 , 54, 4025-6; author reply 4026-7		14
1054	The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. 2006 , 21, 1534-40		37
1053	Kidney biopsy in lupus nephritis: look before you leap. 2006 , 21, 1749-52		41
1052	Further description of early clinically silent lupus nephritis. 2006 , 15, 845-51		39
1051	Renal outcomes in children with lupus and a family history of autoimmune disease. 2006 , 15, 65-70		6
1050	Lupus nephritis in an Afro-Caribbean population: renal indices and clinical outcomes. 2006 , 15, 689-94		12
1049	Current issues in pediatric lupus nephritis: role of revised histopathological classification. 2006 , 25, 297-309		6
1048	Predictive factors of clinical outcome in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy. 2007 , 29, 41-7		8

1047	Autoimmune pancreatitis as the initial presentation of systemic lupus erythematosus. 2007 , 16, 133-6		19
1046	Aberrantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy. 2007 , 18, 3139-46		33
1045	Intrarenal cytokine gene expression in lupus nephritis. 2007 , 66, 886-92		68
1044	Chapter 17 Systemic Lupus Erythematosus: Treatment. 2007 , 7, 323-332		
1043	Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. <i>Kidney International</i> , 2007 , 71, 664-72	9.9	140
1042	Classification of pediatric lupus nephritis. <i>Kidney International</i> , 2007 , 72, 897-8	9.9	2
1041	Human polyomavirus BK in patients with lupus nephritis: clinical and histological correlations. 2007 , 16, 881-6		15
1040	Severe lupus nephritis: racial differences in presentation and outcome. 2007 , 18, 244-54		197
1039	A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. 2007 , 178, 6624-33		374
1038	Emerging minimal-change nephrotic syndrome in a patient with chronic mesangial proliferative lupus nephritis. 2007 , 46, 991-5		6
1037	Lupus Vasculopathy and Vasculitis. 2007 , 12, 214-221		3
1036	[Lupus nephritis]. 2007 , 28 Suppl 4, S304-5		
1035	Difficult diagnoses in renal pathology: Evidence from EQA schemes. 2007 , 13, 1-14		
1034	Recent advances in glomerulonephritis. 2007 , 13, 32-42		1
1033	Upregulated expression of cardiac ankyrin-repeated protein in renal podocytes is associated with proteinuria severity in lupus nephritis. 2007 , 38, 410-9		14
1032	Glomerulonefritis secundarias a enfermedades sistémicas, inflamatorias, infecciosas y disproteinemias. 2007 , 9, 5148-5156		
1031	Clinical features of ANCA-positive systemic lupus erythematosus: report of two cases. 2007 , 36, 74-6		5
1030	The pathology of lupus nephritis. 2007 , 27, 22-34		40

1029	Development of biologicals for the therapy of lupus erythematosus. 2007 , 6, 1001-11		1
1028	Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. 2007 , 36, 291-8		33
1027	The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. <i>Kidney International</i> , 2007 , 71, 491-5	9.9	109
1026	[Lupus membranous nephropathy]. 2007 , 129, 228-35		
1025	Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. 2007 , 56, 924-37		79
1024	Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis. 2007 , 56, 2362-70		83
1023	Maladies Systémiques et Rhumatismes Inflammatoires (Hors PR, SpA et arthropathies métaboliques). 2007 , 74, 29-41		
1022	Clinicopathology of childhood-onset renal systemic lupus erythematosus. 2007 , 12, 364-70		5
1021	Nephrotic syndrome in mesangial proliferative lupus nephritis. 2007 , 49, 1009-11		7
1020	Activation of the lectin complement pathway in post-streptococcal acute glomerulonephritis. 2007 , 57, 351-7		26
1019	Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss. 2007 , 27, 53-68		53
1018	C4d Immunohistochemistry in glomerulonephritis with different antibodies. 2007 , 11, 287-291		18
1017	Clinicopathological correlations of paediatric lupus nephritis. 2007 , 22, 77-83		50
1016	Reduced albumin levels and utilization of arteriovenous access in pediatric patients with systemic lupus erythematosus (SLE). 2007 , 22, 2041-6		10
1015	Identification of a urinary proteomic signature for lupus nephritis in children. 2007 , 22, 2047-57		59
1014	Lupusnephritis. 2007 , 2, 33-36		
1013	Pathologie der Lupus-Nephritis. 2008 , 3, 195-202		
1012	Die Nierenbeteiligung beim systemischen Lupus erythematosus. 2008 , 3, 471-475		

1011	High-titer antichromatin antibody is associated with proliferative class IV of lupus nephritis. 2008 , 27, 1417-21	7
1010	Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan. 2008 , 12, 277-291	20
1009	Lupus nephritis associated with positive MPO-ANCA in a patient with underlying autoimmune hemolytic anemia. 2008 , 12, 393-397	12
1008	A case of systemic lupus erythematosus showing invagination of the podocyte into the glomerular basement membrane: an electron microscopic observation of a repeated-renal biopsy. 2008 , 12, 455-61	5
1007	Unique microstructures and podocytic infolding in glomerular basement membrane associated with collagen diseases: a report of three cases. 2008 , 12, 450-4	9
1006	Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis. 2008 , 23, 83-91	38
1005	Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. 2008 , 23, 403-12	104
1004	Rituximab therapy for juvenile-onset systemic lupus erythematosus. 2008 , 23, 413-9	69
1003	Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen. 2008 , 23, 1877-82	20
1002	Antinucleosome antibodies as a marker of active proliferative lupus nephritis. 2008 , 51, 624-9	39
1001	Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. 2008 , 52, 346-52	20
1000	Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. 2008 , 152, 550-6	222
999	Current therapy of lupus nephritis. Which is the best option?. 2008 , 208, 138-41	
998	Treatment of Lupus Nephritis. 2008 , 4, 140-151	
997	Lupus Nephritis. 2008 , 157-171	1
996	Systemic diseases with renal manifestations. 2008 , 35, 297-328, vi-vii	10
995	Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. 2008 , 69, 840-4	36
994	Intérêt des nouveaux examens sérologiques pour la néphropathie lupique. 2008 , 23, 137-142	

993 [Treatment of lupus nephritis]. **2008**, 4, 140-51

992 Lupus nephritis: the central role of nucleosomes revealed. **2008**, 172, 275-83 73

991 Pathology of lupus nephritis is better classified by the International Society of Nephrology-Renal Pathology Society system. **2008**, 1, 12-17 8

990 Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. **2008**, 17, 281-8 120

989 Can serum autoimmune markers substitute for tissue biopsy in rheumatology?. **2008**, 3, 29-31

988 Lupus nephritis complicated with malignant hypertension: from renal vascular pathology to clinical relevance. **2008**, 23, 81-7 4

987 Pharmacotherapy of lupus nephritis: time for a consensus?. **2008**, 9, 2099-115 2

986 Clinical characteristics of patients with both anti-U1RNP and anti-centromere antibodies. **2008**, 37, 360-4 6

985 Pulmonary hemorrhage, due to rupture of small muscular arteries, in an autopsy case of systemic lupus erythematosus with antiphospholipid antibodies. **2008**, 18, 529-531

984 Long-term outcome of Chinese patients with membranous lupus nephropathy. **2008**, 17, 56-61 38

983 Value of a complete or partial remission in severe lupus nephritis. **2008**, 3, 46-53 177

982 Circulating thrombomodulin and vascular cell adhesion molecule-1 and renal vascular lesion in patients with lupus nephritis. **2008**, 17, 720-6 17

981 Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. **2009**, 48, 513-9 19

980 Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. **2008**, 23, 3521-6 49

979 Multitarget therapy of lupus nephritis: base hit or home run?. **2008**, 19, 1842-4 7

978 Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. **2008**, 3, 682-90 95

977 Pauci-immune and immune glomerular lesions in kidney transplants for systemic lupus erythematosus. **2008**, 3, 1469-78 19

976 Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. **2009**, 24, 172-8 41

975	Systemic Lupus Erythematosus. 2008 , 303-338	6
974	Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. 2008 , 7, 411-9	46
973	Changes in the urinary excretion of beta2-microglobulin (beta 2MG) and N-acetyl-beta-D-glucosaminidase (NAG) during treatment for lupus nephritis. 2008 , 47, 287-90	9
972	Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases. 2008 , 121, 133-136	13
971	Lupus Nephritis. 2008 , 329-342	
970	Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. 2008 , 56, 911-9	15
969	Usefulness of ISN/RPS classification of lupus nephritis. 2009 , 24 Suppl, S7-10	26
968	Non-Neoplastic Kidney. 2009 , 979-1042	
967	Lupus nephritis after remission of membranoproliferative glomerulonephritis in an 11-year-old girl. 2009 , 22, 46-50	
966	Evaluation of renal vascular lesions using thrombomodulin and vascular cell adhesion molecule-1 in patients with biopsy-proven lupus nephritis. 2009 , 1	
965	Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis. <i>Kidney International</i> , 2009 , 75, 1340-1348	9.9 36
964	BioPlex 2200 multiplexed system: simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus. 2009 , 42, 63-8	25
963	The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. 2009 , 48, 1491-7	74
962	Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephritis. 2009 , 36, 2218-23	26
961	Class IV-G and IV-S lupus nephritis in Chinese patients: a large cohort study from a single center. 2009 , 18, 1073-81	32
960	Clinicopathological characteristics of familial SLE patients with lupus nephritis. 2009 , 18, 243-8	7
959	Relevance of anti-C1q autoantibodies to lupus nephritis. 2009 , 1173, 243-51	19
958	Association of interleukin-18 promoter polymorphisms with WHO pathological classes and serum IL-18 levels in Chinese patients with lupus nephritis. 2009 , 18, 29-37	29

957	Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. 2009 , 24, 3717-23	119
956	Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. <i>Kidney International</i> , 2009 , 76, 307-17	99 71
955	Urinary FOXP3 mRNA in patients with lupus nephritis--relation with disease activity and treatment response. 2009 , 48, 755-60	26
954	Evidence of concurrent immunopathological mechanisms determining the pathology of severe lupus nephritis. 2009 , 18, 149-58	15
953	Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. 2009 , 18, 831-5	52
952	European consensus statement on the terminology used in the management of lupus glomerulonephritis. 2009 , 18, 257-63	109
951	Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. 2009 , 20, 2581-92	72
950	Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. 2009 , 4, 579-87	102
949	Lupus podocytopathy. 2009 , 48, 1616-8	20
948	Up-regulated renal expression of TNF-alpha signalling adapter proteins in lupus glomerulonephritis. 2009 , 18, 116-27	25
947	Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. 2009 , 155, 105-10, 110.e1	86
946	How to perform and analyse biopsies in relation to connective tissue diseases. 2009 , 23, 233-55	6
945	Proteinuria in a patient with discoid lupus. 2009 , 54, 567-71	
944	Membranous lupus nephritis in Chinese children--a case series and review of the literature. 2009 , 24, 1989-96	15
943	Semiquantitative and semi-automated morphometric evaluation of chronic lesions in renal biopsies. 2009 , 41, 643-51	2
942	Biomarkers for renal disease in childhood. 2009 , 11, 218-25	15
941	Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. 2009 , 29, 749-54	226
940	Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll-like receptor 2 at the glomerular filtration barrier. 2009 , 128, e206-21	56

939	An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. 2009 , 5, 132-42	25
938	Predominant tubulointerstitial nephritis in a patient with systemic lupus erythematosus with an emphasis on CT and MR imaging findings. 2009 , 72, e87-e90	
937	Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. 2009 , 11, R87	44
936	Vasculitis in children and adolescents: clinical presentation, etiopathogenesis, and treatment. 2009 , 11, 375-80	17
935	Abdominal manifestations of systemic lupus erythematosus: spectrum of imaging findings. 2009 , 60, 121-32	11
934	Glomerular disease: the Oxford classification--predicting progression of IgAN. 2009 , 5, 557-9	6
933	Management of lupus nephritis--current perspectives. 2009 , 4, 153-161	
932	25-Year-Old Man With Flank Pain, Hematuria, and Proteinuria. 2009 , 84, 72-75	
931	Classification of lupus nephritis. 2009 , 18, 220-5	76
930	Current therapies for lupus nephritis in an ethnically heterogeneous cohort. 2009 , 36, 298-305	28
929	Review article: systemic lupus erythematosus: a review for anesthesiologists. 2010 , 111, 665-76	35
928	Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. 2010 , 43, 179-88	38
927	The single nucleotide polymorphisms gene but not the copy number variation of Fcgr3B is associated with lupus nephritis in Chinese people. 2010 , 19, 662-4	7
926	[Systemic lupus erythematosus. A problem based approach]. 2010 , 51, 1013-26; quiz 1027-8	4
925	Male gender results in more severe lupus nephritis. 2010 , 30, 1311-5	40
924	Analysis of clinical manifestations and pathology of lupus nephritis: a retrospective review of 82 cases. 2010 , 29, 1175-80	23
923	The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis. 2010 , 25, 111-7	14
922	IgG subclasses and complement pathway in segmental and global membranous nephropathy. 2010 , 25, 1091-9	77

921	Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. 2010 , 25, 2283-8	50
920	Single anti-P ribosomal antibodies are not associated with lupus nephritis in patients suffering from active systemic lupus erythematosus. 2010 , 9, 750-5	14
919	Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. 2010 , 99, 967-74	27
918	Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus. 2010 , 62, 3436-46	65
917	Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. 2010 , 159, 1-10	98
916	Association of IRF5 gene polymorphisms and lupus nephritis in a Chinese population. 2010 , 15, 710-3	25
915	Rheumatoid Arthritis/SLE. 267-281	
914	AUTOIMMUNITY AND THE MUSCULOSKELETAL SYSTEM. 2010 , 123-135	
913	Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. 2010 , 19, 1591-8	24
912	Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. 2010 , 49, 520-7	118
911	Case records of the Massachusetts General Hospital. Case 37-2010. A 16-year-old girl with confusion, anemia, and thrombocytopenia. 2010 , 363, 2352-61	7
910	The detrimental effects of IFN- β on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. 2010 , 185, 4457-69	98
909	Lupus Nephritis. 2010 , 308-321	3
908	Revisi3n general de compromiso renal en enfermedades autoinmunes. 2010 , 21, 597-601	
907	Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus. 2010 , 20, 291-294	10
906	The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. 2010 , 37, 2046-52	84
905	Major lupus organ involvement: severe lupus nephritis. 2010 , 19, 1391-8	21
904	Treatment of lupus nephritis. 2010 , 6, 901-11	11

903	Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. <i>Kidney International</i> , 2010 , 77, 820-9	9.9	145
902	Lupus nephritis combined with renal injury due to thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome. 2010 , 25, 145-52		23
901	Expression of Toll-like receptor 9 in renal podocytes in childhood-onset active and inactive lupus nephritis. 2010 , 25, 2530-537		35
900	High-sensitivity C-reactive protein: an independent risk factor for left ventricular hypertrophy in patients with lupus nephritis. 2010 , 2010, 373426		8
899	Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). 2010 , 25, 2168-77		114
898	Caring for adolescent renal patients. <i>Kidney International</i> , 2010 , 77, 285-91	9.9	8
897	Ocena przebiegu oraz skuteczności stosowanego leczenia toczniowego zapalenia nerek u dzieci. 2010 , 85, 328-335		
896	Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. 2010 , 19, 557-74		151
895	Sindrome da anticorpi antifosfolipidi primaria (PAPS): descrizione di un caso clinico evoluto in lupus eritematoso sistemico. 2010 , 4, 116-121		
894	Pharmacokinetics of mycophenolic acid in severe lupus nephritis. <i>Kidney International</i> , 2010 , 78, 389-95	9.9	56
893	Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. 2010 , 5, 770-82		130
892	Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus. 2010 , 20, 168-177		5
891	Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis. 2011 , 20, 1404-10		25
890	Lupus nephritis: role of antinucleosome autoantibodies. 2011 , 31, 376-89		61
889	Diagnosis and management of juvenile-onset SLE. 2011 , 21, 539-545		2
888	[Renal p-ANCA vasculitis in patients with systemic lupus erythematosus]. 2011 , 137, 379-80		2
887	Acute kidney injury in Chinese patients with lupus nephritis: a large cohort study from a single center. 2011 , 20, 1557-65		20
886	Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. 2011 , 31, 341-8		136

885	Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. 2011 , 13, R26	28
884	Anti-C1q and anti-dsDNA antibodies in systemic lupus erythematosus: Relationship with disease activity and renal involvement in Sharkia governorate, Egypt. 2011 , 33, 203-208	7
883	The SLAM family member CD48 (Slamf2) protects lupus-prone mice from autoimmune nephritis. 2011 , 37, 48-57	20
882	Quels auto-anticorps pour le diagnostic et le suivi de la n̄phropathie lupique ?. 2011 , 26, 113-117	0
881	Late onset lupus nephritis in Chinese patients: classified by the 2003 International Society of Nephrology and Renal Pathology Society system. 2011 , 20, 801-8	10
880	Enfermedad renal cr̄nica: clasificacīn, etiopatogenia y factores pron̄sticos. 2011 , 10, 5364-5369	
879	Glomerulopat̄as secundarias a enfermedades sist̄micas. 2011 , 10, 5560-5580	
878	Mujer joven con astenia, rash malar y deterioro de la funcīn renal. 2011 , 10, 5594.e1-5594.e3	
877	OX40/OX40L in systemic lupus erythematosus: association with disease activity and lupus nephritis. 2011 , 31, 29-34	30
876	S. 370-395	
875	Complement and Tissue Injury in SLE. 2011 , 339-363	
874	Clearing the complexity: immune complexes and their treatment in lupus nephritis. 2011 , 4, 17-28	15
873	SYSTEMIC LUPUS ERYTHEMATOSUS. 2011 , 315-343	20
872	Gene expression of TWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. 2011 , 16, 426-32	43
871	Ethnicity and lupus nephritis: an Australian single centre study. 2011 , 41, 270-8	23
870	Lupus nephropathy and vasculitis. 2011 , 39, 486-491	2
869	Antibodies to ribosomal P proteins in lupus nephritis: a surrogate marker for a better renal survival?. 2011 , 10, 126-30	22
868	Epidemiology and management of refractory lupus nephritis. 2011 , 10, 655-63	44

867	Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. 2011 , 187, 538-52	793
866	[Systemic lupus erythematosus]. 2011 , 70, 313-23	4
865	Renal biopsy findings in new-onset systemic lupus erythematosus with clinical renal disease. 2011 , 43, 801-6	9
864	Increased risk of death in pediatric and adult patients with ESRD secondary to lupus. 2011 , 26, 93-8	46
863	Problems with focal segmental glomerulosclerosis. 2011 , 26, 1197-205	13
862	Children with posterior reversible encephalopathy syndrome associated with atypical diffusion-weighted imaging and apparent diffusion coefficient. 2011 , 15, 275-80	16
861	Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians. 2011 , 15, 321-330	13
860	Glomerular antibodies in lupus nephritis. 2011 , 40, 151-8	44
859	Histopathology of lupus nephritis. 2011 , 40, 170-80	27
858	Nierenbeteiligung beim systemischen Lupus erythematosus. 2011 , 6, 258-264	1
857	Treatment of lupus nephritis. 2011 , 13, 283-90	6
856	Heparin exerts a dual effect on murine lupus nephritis by enhancing enzymatic chromatin degradation and preventing chromatin binding in glomerular membranes. 2011 , 63, 1065-75	33
855	Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. 2011 , 63, 2436-44	50
854	Intrarenal production of B-cell survival factors in human lupus nephritis. 2011 , 24, 98-107	49
853	Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. 2011 , 50, 1578-85	55
852	Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis. 2011 , 16, 393-404	16
851	Podocyte main slit diaphragm proteins, nephrin and podocin, are affected at early stages of lupus nephritis and correlate with disease histology. 2011 , 20, 781-91	47
850	The 2010 nephrology quiz and questionnaire: part 2. 2011 , 6, 2534-47	2

849	Three decades of progress in treating childhood-onset lupus nephritis. 2011 , 6, 2192-9	45
848	High risk of ischemic heart disease in patients with lupus nephritis. 2011 , 38, 2400-5	27
847	Auto-antibody production and glomerulonephritis in congenic Slamf1 ^{-/-} and Slamf2 ^{-/-} [B6.129] but not in Slamf1 ^{-/-} and Slamf2 ^{-/-} [BALB/c.129] mice. 2011 , 23, 149-58	18
846	Repeat renal biopsy in lupus nephritis: a change in histological pattern is common. 2011 , 34, 220-5	35
845	Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. 2011 , 6, 1009-17	114
844	Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. 2011 , 20, 28-34	67
843	Predictors of mortality and end stage renal disease in Saudi patients with lupus nephritis. 2011 , 20, 1329-35	17
842	Simultaneous presentation of systemic lupus erythematosus and lupus nephritis in mother and son. 2011 , 20, 1541-6	1
841	Minimal change disease: a variant of lupus nephritis. 2011 , 4, 20-2	4
840	Th subset balance in lupus nephritis. 2011 , 2011, 980286	53
839	Illness perceptions in patients with systemic lupus erythematosus and proliferative lupus nephritis. 2011 , 20, 290-8	37
838	Kidney. 2011 , 769-814	8
837	Urinary monocyte chemotactic protein-1 and transforming growth factor- β in systemic lupus erythematosus. 2012 , 22, 5-12	15
836	Differential diagnosis of lupus and primary membranous nephropathies by IgG subclass analysis. 2012 , 7, 1947-55	13
835	Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. 2012 , 7, 1591-7	158
834	Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study. 2012 , 21, 13-26	33
833	Clinicopathological insights into lupus nephritis in South Africans: a study of 251 patients. 2012 , 21, 1017-24	17
832	Relationship of intrarenal gene expression and the histological class of lupus nephritis -- a study on repeat renal biopsy. 2012 , 39, 1942-7	12

831	Renal-limited Lupus-like Nephritis. 2012 , 27, 2337-42	38
830	Early treatment with glucocorticoids or cyclophosphamide retains the slit diaphragm proteins nephrin and podocin in experimental lupus nephritis. 2012 , 21, 1196-207	11
829	Activated CD4+ T cells target mesangial antigens and initiate glomerulonephritis. 2012 , 121, e1-9	8
828	Risk factors for renal failure in patients with lupus nephritis: data from the spanish registry of glomerulonephritis. 2012 , 2, 269-77	14
827	Strategy for second kidney biopsy in patients with lupus nephritis. 2012 , 27, 1472-8	52
826	Complete remission in severe lupus nephritis: assessing the rate of loss in proteinuria. 2012 , 27, 2813-9	15
825	Clinical Pathway for Monthly Pulse Intravenous Cyclophosphamide Therapy for Lupus Nephritis. 2012 , 42, 278-282	1
824	A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. 2012 , 227, 281-8	27
823	Lupus nephritis: Transatlantic management recommendations compared. 2012 , 8, 697-8	1
822	Idiopathic membranoproliferative glomerulonephritis: does it exist?. 2012 , 27, 4288-94	34
821	Management of lupus nephritis. 2012 , 7, 69-79	
820	Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis. 2012 , 51, 2269-77	32
819	American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. 2012 , 64, 797-808	863
818	Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. 2012 , 64, 3660-5	119
817	Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis. 2012 , 31, 1323-9	18
816	Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. 2012 , 22, 50-7	87
815	Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. 2012 , 7, 757-64	35
814	Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. 2012 , 27, 3552-9	48

813	Urinary proteomics revealed prostaglandin H(2)D-isomerase, not Zn- α -glycoprotein, as a biomarker for active lupus nephritis. 2012 , 75, 3240-7	32
812	[A 28-years old pregnant woman with systemic lupus erythematosus, proteinuria and arterial hypertension]. 2012 , 139, 489-97	0
811	Case records of the Massachusetts General Hospital. Case 32-2012. A 35-year-old man with respiratory and renal failure. 2012 , 367, 1540-53	5
810	Silencing of renal DNaseI in murine lupus nephritis imposes exposure of large chromatin fragments and activation of Toll like receptors and the Clec4e. 2012 , 7, e34080	19
809	Urinary hypoxia-inducible factor-1alpha levels are associated with histologic chronicity changes and renal function in patients with lupus nephritis. 2012 , 53, 587-92	13
808	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. 2012 , 64, 2677-86	2688
807	Outcome of reclassification of World Health Organization (WHO) class III under International Society of Nephrology-Renal Pathology Society (ISN-RPS) classification: retrospective observational study. 2012 , 32, 1877-84	6
806	ISN/RPS 2003 class II mesangial proliferative lupus nephritis: a comparison between cases that progressed to class III or IV and cases that did not. 2012 , 32, 2459-64	13
805	[Renal emergencies in cases of collagenosis and vasculitis]. 2012 , 71, 270-7	
804	Historical milestones in renal pathology. 2012 , 461, 3-11	20
803	Recent advances in the treatment of lupus nephritis. 2012 , 16, 202-13	9
802	Glomerulonephritis with crescents among adult Saudi patients outcome and its predictors. 2012 , 12, 121-5	10
801	Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. 2012 , 17, 346-51	88
800	Simultaneous positivity for anti-DNA, anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis. 2013 , 33, 378-87	32
799	The spectrum of renal thrombotic microangiopathy in lupus nephritis. 2013 , 15, R12	130
798	Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus. 2013 , 15, R18	26
797	Anti-C1q antibodies and systemic lupus erythematosus in the Tunisian population. 2013 , 61, 113-6	7
796	AP-VAS 2012 case report: a case of lupus nephritis with predominant synchronous cellular crescent formation and myeloperoxidase-antineutrophil cytoplasmic antibody seropositivity. 2013 , 2, 134-138	2

795	[Statement on the use of mycophenolate mofetil for systemic lupus erythematosus]. 2013 , 72, 575-80	3
794	Improving outcomes in patients with lupus and end-stage renal disease. 2013 , 26, 590-6	15
793	Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis. 2013 , 38, 445-52	19
792	Interstitial inflammation and long-term renal outcomes in lupus nephritis. 2013 , 22, 1446-54	40
791	Urinary free light chain is a potential biomarker for ISN/RPS class III/IV lupus nephritis. 2013 , 52, 2149-57	16
790	Overview of lupus nephritis management guidelines and perspective from Asia. 2013 , 16, 625-36	25
789	Long-term follow-up of autologous stem cell transplantation for severe paediatric systemic lupus erythematosus. 2013 , 32, 1727-34	16
788	Neue Klassifikationssysteme in der Nierenpathologie. 2013 , 8, 465-467	
787	Renaler Lupus erythematosus. 2013 , 8, 474-482	0
786	Was bringen nephropathologische Klassifikationen für den klinisch tätigen Nephrologen?. 2013 , 8, 468-473	3
785	Rheumatic Disease. 2013 , 1415-1440	
784	Systemic Lupus Erythematosus. 2013 , 107-121	
783	Could women with systemic lupus erythematosus (SLE) have successful pregnancy outcomes? Prospective observational study. 2013 , 35, 133-139	9
782	Anticuerpos Anti-C1q como marcadores de compromiso renal en pacientes con lupus eritematoso sistémico. 2013 , 20, 195-201	2
781	Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aprevia Lupus Management Study. 2013 , 61, 710-5	39
780	Lupus eritematoso sistémico (II). 2013 , 11, 1966-1974	
779	Impact of the tumor necrosis factor receptor-associated protein 1 (Trap1) on renal DNase1 shutdown and on progression of murine and human lupus nephritis. 2013 , 182, 688-700	17
778	Pauci-immune necrotizing crescentic glomerulonephritis with crescentic and full moon extracapillary proliferation: clinico-pathologic correlation and follow-up study. 2013 , 209, 75-82	16

777	Pathology, classification and pathogenesis of lupus glomerulonephritis. 2013 , 19, 151-157		2
776	Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis?. 2013 , 8, 138-45		63
775	The rise of renal pathology in nephrology: structure illuminates function. 2013 , 61, 1016-25		25
774	C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. 2013 , 46, 205-14		26
773	Clinical and Epidemiologic Features of Lupus Nephritis. 2013 , 438-454		3
772	When and how to perform biopsies in a patient with a (suspected) connective tissue disease. 2013 , 27, 209-36		3
771	Insertion/deletion polymorphism of the angiotensin-converting enzyme gene in lupus nephritis among Mexicans. 2013 , 35, 174-80		5
770	TULUP (TUnisian LUPus): a multicentric study of systemic lupus erythematosus in Tunisia. 2013 , 16, 539-46		25
769	Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. <i>Kidney International</i> , 2013 , 83, 715-23	9.9	98
768	The pathogenesis of lupus nephritis. 2013 , 24, 1357-66		245
767	A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial. 2013 , 3,		2
766	Rare transformation in repeat renal biopsies suggests a different pathogenesis of segmental and global lesions in proliferative lupus nephritis. 2013 , 28, 2929-32		3
765	Manifestations cliniques et biologiques Diagnostic du lupus fytthmateux. 2013 , 41-72		1
764	NADPH oxidase and nitric oxide synthase-dependent superoxide production is increased in proliferative lupus nephritis. 2013 , 22, 1361-70		9
763	ABIN1 dysfunction as a genetic basis for lupus nephritis. 2013 , 24, 1743-54		59
762	Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. 2013 , 22, 1523-5		14
761	Renal Disease. 2013 , 1-54		
760	Severe lupus nephritis: the predictive value of a 50% reduction in proteinuria at 6 months. 2013 , 28, 2313-8		34

759	Selected Topics in Systemic Lupus Erythematosus: B Cells in Lupus and Lupus Nephritis. 2013 , 39-53	
758	Renal biopsy pathology in a cohort of patients from southwest Sydney with clinically diagnosed systemic lupus erythematosus. 2013 , 6, 15-26	9
757	A study on clinical and pathologic features in lupus nephritis with mainly IgA deposits and a literature review. 2013 , 2013, 289316	6
756	Comparative effects of n-3, n-6 and n-9 unsaturated fatty acid-rich diet consumption on lupus nephritis, autoantibody production and CD4+ T cell-related gene responses in the autoimmune NZBWF1 mouse. 2014 , 9, e100255	42
755	Clinicopathological characteristics and outcomes of Chinese patients with scanty immune deposits lupus nephritis: a large cohort study from a single center. 2014 , 2014, 212597	2
754	Classifying lupus nephritis: an ongoing story. 2014 , 2014, 580620	14
753	Relationship between hypoalbuminemia, hyperlipidemia and renal severity in patients with lupus nephritis: a prospective study. 2014 , 39, 243-52	14
752	Chemokine receptor 5 (CCR5) delta 32 polymorphism in lupus nephritis: a large case-control study and meta-analysis. 2014 , 47, 383-8	5
751	Value of repeat biopsy in lupus nephritis flares. 2014 , 1, e000004	29
750	Animal models of renal disease. 2014 , 11, 1-4	2
749	Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis. 2014 , 3, 638	4
748	Acute kidney injury associated with minimal change disease in systemic lupus erythematosus: a case report. 2014 , 8, 422	
747	The Steroids In the Maintenance of remission of Proliferative Lupus nephritis (SIMPL) pilot trial. 2014 , 1, 30	20
746	Rheumatological diseases and kidneys: a nephrologist's perspective. 2014 , 17, 834-44	15
745	A study of hepcidin and monocyte chemoattractant protein-1 in Egyptian females with systemic lupus erythematosus. 2014 , 28, 306-9	12
744	Long-term data on tacrolimus treatment in lupus nephritis. 2014 , 53, 2232-7	37
743	Parasites alter the pathological phenotype of lupus nephritis. 2014 , 47, 538-47	11
742	Editorial: autoimmunity to vimentin and lupus nephritis. 2014 , 66, 3251-4	10

741	Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden. 2015 , 30 Suppl 1, i23-30	8
740	Estimation of kidney injury molecule-1 (Kim-1) in patients with lupus nephritis. 2014 , 23, 769-77	22
739	Serum milk fat globule epidermal growth factor 8 elevation may subdivide systemic lupus erythematosus into two pathophysiologically distinct subsets. 2014 , 23, 386-94	17
738	The management of lupus nephritis. 2014 , 39, 1-6	2
737	Metabolic syndrome is correlated with carotid atherosclerosis in patients with lupus nephritis. 2014 , 348, 486-91	11
736	Diverse vascular lesions in systemic lupus erythematosus and clinical implications. 2014 , 23, 218-23	5
735	Three cases of lupus nephritis patients with serum interleukin-32 detection. 2014 , 23, 1187-91	5
734	Identification of novel autoantibodies to GABA(B) receptors in patients with neuropsychiatric systemic lupus erythematosus. 2014 , 53, 1219-28	17
733	Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus. 2014 , 17, 790-5	11
732	4G/5G plasminogen activator inhibitor-1 and -308 A/G tumor necrosis factor- β promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis. 2014 , 14, 83-9	7
731	Overview of lupus nephritis management guidelines and perspective from Asia. 2014 , 19, 11-20	48
730	Anti-ribosomal-P antibodies accelerate lupus glomerulonephritis and induce lupus nephritis in naïve mice. 2014 , 54, 118-26	11
729	Focal and Segmental Glomerulosclerosis. 2014 , 33-49	
728	Membranoproliferative Glomerulonephritis. 2014 , 77-85	1
727	Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) on kidney tissue from systemic lupus erythematosus (SLE) patients. 2014 , 14, 383-8	14
726	[Recipes systemic lupus erythematosus]. 2014 , 73, 496-500	3
725	Glomerular Clinicopathologic Syndromes. 2014 , 152-163	2
724	The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. 2014 , 23, 840-7	53

723	A case of steroid-resistant nephrotic syndrome associated with systemic lupus erythematosus. 2014 , 23, 703-6	8	
722	Noninflammatory necrotizing vasculopathy in lupus nephritis: a single-center experience. 2014 , 23, 20-30	10	
721	Glomerular Diseases. 2014 , 141-229	1	
720	The clinical significance of serial kidney biopsies in lupus nephritis. 2014 , 24, 453-6	13	
719	The serum levels of connective tissue growth factor in patients with systemic lupus erythematosus and lupus nephritis. 2014 , 23, 655-64	3	
718	Long-term outcome in Japanese patients with lupus nephritis. 2014 , 23, 1124-32	29	
717	Renal tubular acidosis in Sjögren's syndrome: a case series. 2014 , 40, 123-30	15	
716	Increased urinary interleukin 22 binding protein levels correlate with lupus nephritis activity. 2014 , 41, 1793-800	9	
715	Classification Systems in Renal Pathology: Promises and Problems. 2014 , 7, 427-41	5	
714	The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. 2014 , 36, 301-11	60	
713	Chest imaging manifestations in lupus nephritis. 2014 , 33, 817-23	1	
712	[Proliferative lupus nephritis treatment: practice survey in nephrology and internal medicine in France]. 2014 , 10, 170-6	1	
711	Urine miRNA in nephrotic syndrome. 2014 , 436, 308-13	34	
710	Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. 2014 , 41, 1998-2007	30	
709	Clinicopathological characteristics of lupus nephritis in Western region of Saudi Arabia: An experience from two tertiary medical centres. 2014 , 2, 12	1	
708	Anti-nucleosome antibodies: A potential surrogate marker for renal affection in lupus patients with insignificant proteinuria. 2014 , 36, 79-84	10	
707	Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. <i>Kidney International</i> , 2014 , 85, 779-93	9.9	40
706	Where is lupus hidden?. 2014 , 43, e143-50	1	

705	Interleukin 1, interleukin 6, interleukin 10, and tumor necrosis factor β in active and quiescent systemic lupus erythematosus. 2014 , 62, 825-9	36
704	Biologic agents in the treatment of glomerulonephritides. 2015 , 20, 767-87	3
703	Clinical significance of anti-C1q antibodies in SLE. 2015 , 62, 15-20	
702	Successful Management of Lupus Nephritis with High Titers of Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibodies Using Tacrolimus. 2015 , 54, 2929-33	4
701	How I diagnose and treat lupus. 2015 , 17, 59-63	
700	Update on the management of lupus nephritis. 2015 , 12, 10-15	
699	The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis. 2015 , 67, 1858-67	14
698	Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis. 2015 , 9, 1012-20	31
697	Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin. 2015 , 67, 3190-200	166
696	Epidemiology and risk factors for chronic kidney disease in Chinese patients with biopsy-proven lupus nephritis. 2015 , 45, 1167-72	6
695	Pulmonary hemorrhage as an unusual initial manifestation of systemic lupus erythematosus. 2015 , 3, 370	
694	Silica Triggers Inflammation and Ectopic Lymphoid Neogenesis in the Lungs in Parallel with Accelerated Onset of Systemic Autoimmunity and Glomerulonephritis in the Lupus-Prone NZBWF1 Mouse. 2015 , 10, e0125481	43
693	The Role of Personality and Social Support in Health-Related Quality of Life in Chronic Kidney Disease Patients. 2015 , 10, e0129015	33
692	Renal Interstitial Arteriosclerotic Lesions in Lupus Nephritis Patients: A Cohort Study from China. 2015 , 10, e0141547	12
691	An unusual initial presentation of lupus nephritis as a renal mass. 2015 , 2015, 231974	0
690	Fetal microchimerism in kidney biopsies of lupus nephritis patients may be associated with a beneficial effect. 2015 , 17, 101	5
689	David S. Baldwin, MD: a legacy in nephrology. 2015 , 26, 531-5	
688	Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. 2015 , 17, 371	12

687	Significance of CD163-Positive Macrophages in Proliferative Glomerulonephritis. 2015 , 350, 387-92	24
686	A clinical study of lupus nephritis in a tertiary care hospital in northeast India. 2015 , 6, 136-140	0
685	Incidence and prognosis of systemic lupus erythematosus in a 35 year period in Fukushima, Japan. 2015 , 57, 650-5	4
684	Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis. 2015 , 55, 1-21	3
683	Effect of Rituximab on Serum Levels of Anti-C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus Nephritis. 2015 , 72, 197-201	21
682	Spot urine protein/creatinine ratio is unreliable estimate of 24 h proteinuria in lupus nephritis when the histological scores of activity index are higher. 2015 , 24, 943-7	8
681	The multifaceted aspects of refractory lupus nephritis. 2015 , 11, 281-8	11
680	Renal infarction due to lupus vasculopathy. 2015 , 24, 985-9	2
679	Intrarenal and Urinary Th9 and Th22 Cytokine Gene Expression in Lupus Nephritis. 2015 , 42, 1150-5	11
678	Biomarkers for kidney involvement in pediatric lupus. 2015 , 9, 529-43	14
677	Morphology in the Digital Age: Integrating High-Resolution Description of Structural Alterations With Phenotypes and Genotypes. 2015 , 35, 266-78	19
676	Lupus nephropathy and vasculitis. 2015 , 43, 538-544	2
675	Immunosuppressive Therapies for the Maintenance Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis. 2015 , 42, 1392-400	20
674	Risk factors for renal disease in systemic lupus erythematosus and their clinical implications. 2015 , 11, 837-48	8
673	The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions. 2015 , 26, 2938-46	40
672	Long-term renal outcomes of childhood-onset global and segmental diffuse proliferative lupus nephritis. 2015 , 30, 1969-76	20
671	Human neutrophil peptide 1-3, a component of the neutrophil extracellular trap, as a potential biomarker of lupus nephritis. 2015 , 18, 533-40	11
670	Pathological spectrums and renal prognosis of severe lupus patients with rapidly progressive glomerulonephritis. 2015 , 35, 709-17	11

- 669 Immunosuppressive Therapie der Lupusnephritis. **2015**, 10, 24-30
- 668 Con: kidney biopsy: an irreplaceable tool for patient management in nephrology. **2015**, 30, 528-31 12
- 667 Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study. **2015**, 24, 1067-75 14
- 666 Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. **2015**, 17, 109 23
- 665 Prediction of renal outcomes in patients with crescentic lupus nephritis. **2015**, 349, 298-305 12
- 664 Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. **2015**, 25, 854-7 4
- 663 Molecular studies of lupus nephritis kidneys. **2015**, 63, 187-96 8
- 662 Methylprednisolone attenuates lipopolysaccharide-induced Fractalkine expression in kidney of Lupus-prone MRL/lpr mice through the NF-kappaB pathway. **2015**, 16, 148 14
- 661 The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis. **2015**, 35, 455-64 48
- 660 [Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis]. **2015**, 55, 1-21 30
- 659 Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China. **2015**, 24, 546-57 13
- 658 Treatment of severe lupus nephritis: the new horizon. **2015**, 11, 46-61 67
- 657 Presentation and outcome of paediatric membranous non-proliferative lupus nephritis. **2015**, 30, 113-21 16
- 656 Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. **2015**, 30, 1185-92 69
- 655 Cleaved Form of Osteopontin in Urine as a Clinical Marker of Lupus Nephritis. **2016**, 11, e0167141 18
- 654 Lupus nephritis in children - 10 yearsKexperience. **2016**, 41, 248-254 11
- 653 Pentraxin 3 Is Closely Associated With Tubulointerstitial Injury in Lupus Nephritis: A Large Multicenter Cross-Sectional Study. **2016**, 95, e2520 22
- 652 Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). **2016**, 95, e2891 32

651	Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis. 2016 , 22, 299-306	11
650	Recurrent lupus nephritis after transplantation: Clinicopathological evaluation with protocol biopsies. 2016 , 21, 601-7	11
649	Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis. 2016 , 184, 11-8	17
648	Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults. 2016 , 68, 1003-11	42
647	Advances in the diagnosis and classification of systemic lupus erythematosus. 2016 , 12, 1309-1320	24
646	Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study. 2016 , 17, 145	5
645	Relation of peritubular capillary features to class of lupus nephritis. 2016 , 17, 169	2
644	Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. 2017 , 56, 477-487	21
643	Enfermedades autoinmunes sistémicas en atención primaria. 2016 , 23, 513-527	
642	Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease. 2016 , 25, 1440-1447	15
641	Urinary congophilia in women with hypertensive disorders of pregnancy and preexisting proteinuria or hypertension. 2016 , 215, 464.e1-7	25
640	Evaluating the association of interleukin-10 gene promoter -592 A/C polymorphism with lupus nephritis susceptibility. 2016 , 35, 29-34	13
639	Standard of treatment and outcomes of adults with lupus nephritis in Africa: a systematic review. 2016 , 25, 1269-77	7
638	miR-148a-3p overexpression contributes to glomerular cell proliferation by targeting PTEN in lupus nephritis. 2016 , 310, C470-8	41
637	Conventional Treatment of Systemic Lupus Erythematosus. 2016 , 213-238	
636	Effect of Autoantibodies to Erythropoietin Receptor in Systemic Lupus Erythematosus with Biopsy-proven Lupus Nephritis. 2016 , 43, 1328-34	10
635	Pro: Cyclophosphamide in lupus nephritis. 2016 , 31, 1047-52	6
634	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—the Berlin Roadmap. 2016 , 1, 327-339	1

633	Beta2-glycoprotein I Expression in Lupus Nephritis Patients with Antiphospholipid-associated Nephropathy. 2016 , 43, 2026-2032		3
632	Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis. <i>Kidney International</i> , 2016 , 90, 1357-1367	9.9	14
631	Membranous Lupus Nephritis: The Same, But Different. 2016 , 68, 954-966		17
630	Proteomics and glomerulonephritis: A complementary approach in renal pathology for the identification of chronic kidney disease related markers. 2016 , 10, 371-83		16
629	Blunting Autoantigen-induced FOXO3a Protein Phosphorylation and Degradation Is a Novel Pathway of Glucocorticoids for the Treatment of Systemic Lupus Erythematosus. 2016 , 291, 19900-12		9
628	Whole-genome transcription and DNA methylation analysis of peripheral blood mononuclear cells identified aberrant gene regulation pathways in systemic lupus erythematosus. 2016 , 18, 162		68
627	Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies. 2016 , 124, 725-35		7
626	Vasculitis in Connective Tissue Diseases. 2016 , 345-359		
625	The Impact of Baseline Serum Creatinine on Complete Remission Rate and Long-Term Outcome in Patients with Severe Lupus Nephritis. 2016 , 6, 12-21		4
624	Systemic Lupus Erythematosus. 2016 , 1-6		
623	Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. 2016 , 18, 243		7
622	Vitamin D Deficiency in Egyptian Systemic Lupus Erythematosus Patients: How Prevalent and Does It Impact Disease Activity?. 2016 , 11, 27-33		19
621	Renal Thrombotic Microangiopathy in Proliferative Lupus Nephritis: Risk Factors and Clinical Outcomes: A Case-Control Study. 2016 , 22, 235-40		14
620	Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. 2016 , 95, e3748		43
619	Lupusnephritis. 2016 , 11, 134-141		
618	Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients. 2016 , 22, 75-9		3
617	Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. 2016 , 31, 2023-2033		40
616	Lupus nephritis: When and how often to biopsy and what does it mean?. 2016 , 74, 27-40		35

615	Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis. 2016 , 68, 2806-2816	67
614	Clinical-Morphological Features and Outcomes of Lupus Podocytopathy. 2016 , 11, 585-92	62
613	Predicting decline of kidney function in lupus nephritis using urine biomarkers. 2016 , 25, 1012-8	24
612	Impact of anti-glomerular basement membrane antibodies and glomerular neutrophil activation on glomerulonephritis in experimental myeloperoxidase-antineutrophil cytoplasmic antibody vasculitis. 2016 , 31, 574-85	16
611	What is damaging the kidney in lupus nephritis?. 2016 , 12, 143-53	146
610	Etiology and Outcome of Crescentic Glomerulonephritis From a Single Center in China: A 10-Year Review. 2016 , 67, 376-83	25
609	Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. 2016 , 15, 93-101	87
608	Differential activation mechanisms of serum C5a in lupus nephritis and neuropsychiatric systemic lupus erythematosus. 2017 , 27, 292-297	12
607	Clinical features and outcome of lupus myocarditis in the Western Cape, South Africa. 2017 , 26, 38-47	14
606	Increased Mer and Axl receptor tyrosine kinase expression on glomeruli in lupus nephritis. 2017 , 36, 1063-1070	4
605	Prognostic significance of renal vascular pathology in lupus nephritis. 2017 , 26, 1042-1050	23
604	Analysis of FOXP3 regulatory T cell subpopulations in peripheral blood and tissue of patients with systemic lupus erythematosus. 2017 , 65, 551-563	19
603	Renal biopsy in patients with lupus: Not just lupus nephritis!. 2017 , 41, 98-98	1
602	BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis. 2017 , 198, 2602-2611	43
601	Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients. 2017 , 36, 351-359	11
600	Lupus eritematoso sistémico (l). Etiopatogenia. Manifestaciones clínicas. Historia natural. Pruebas diagnósticas. Diagnóstico diferencial. 2017 , 12, 1429-1439	
599	Renal biopsy in patients with systemic lupus erythematosus: Not just lupus glomerulonephritis!. 2017 , 41, 135-146	3
598	Interferon regulatory factor 5 gene polymorphism in Egyptian children with systemic lupus erythematosus. 2017 , 26, 871-880	15

597	Comparative Effectiveness of Mycophenolate Mofetil for the Treatment of Juvenile-Onset Proliferative Lupus Nephritis. 2017 , 69, 1887-1894	8
596	Complement Alternative Pathway's Activation in Patients With Lupus Nephritis. 2017 , 353, 247-257	33
595	Anti-pentraxin 3 auto-antibodies might be protective in lupus nephritis: a large cohort study. 2017 , 39, 465-473	11
594	Genetic variants in FH are associated with renal histopathologic subtypes of lupus nephritis: a large cohort study from China. 2017 , 26, 1309-1317	8
593	Inter-observer variability of the histological classification of lupus glomerulonephritis in children. 2017 , 26, 1205-1211	17
592	Digital pathology imaging as a novel platform for standardization and globalization of quantitative nephropathology. 2017 , 10, 176-187	34
591	Broad Concepts in Management of Systemic Lupus Erythematosus. 2017 , 92, 744-761	10
590	Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis. 2017 , 12, 734-743	68
589	Systematic review of the literature on reproducibility of the interpretation of renal biopsy in lupus nephritis. 2017 , 26, 1502-1512	13
588	Ischemia-induced glomerular parietal epithelial cells hyperplasia: Commonly misdiagnosed cellular crescent in renal biopsy. 2017 , 213, 982-986	2
587	Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults. 2017 , 44, 1239-1248	25
586	Lupus Nephritis in Males: Clinical Features, Course, and Prognostic Factors for End-Stage Renal Disease. 2017 , 2, 905-912	6
585	Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience. 2017 , 26, 1564-1570	16
584	Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. 2017 , 16, 826-832	38
583	Significance of M2 macrophages in glomerulonephritis with crescents. 2017 , 213, 1215-1220	20
582	Autoantibodies against C-Reactive Protein Influence Complement Activation and Clinical Course in Lupus Nephritis. 2017 , 28, 3044-3054	29
581	Renal involvement in systemic lupus erythematosus: glomerular pathology, classification, and future directions. 2017 , 23, 109-116	2
580	Idiopathic non-lupus full-house nephropathy is associated with poor renal outcome. 2017 , 32, 654-662	21

579	Urinary and tissue monocyte chemoattractant protein1 (MCP1) in lupus nephritis patients. 2017 , 39, 145-150		11
578	Expression of T helper 17 cells and interleukin 17 in lupus nephritis patients. 2017 , 39, 151-157		8
577	Temporal and Demographic Trends in Glomerular Disease Epidemiology in the Southeastern United States, 1986-2015. 2017 , 12, 614-623		69
576	Recurrent podocytopathy in a patient with systemic lupus erythematosus. 2017 , 5, 2050313X17695997		1
575	Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. 2017 , 50, 257-268		10
574	Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. 2017 , 185, 3-9		8
573	Do ANCAs make the difference in lupus nephritis?. <i>Kidney International</i> , 2017 , 92, 1048-1050	9.9	3
572	Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. 2017 , 37, 447-463		13
571	Cellular and Molecular Mechanisms of Autoimmunity and Lupus Nephritis. 2017 , 332, 43-154		8
570	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. 2017 , 76, 1965-1973		65
569	Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. <i>Kidney International</i> , 2017 , 92, 1223-1231	9.9	40
568	Treatment and clinicopathological characteristics of lupus nephritis with anti-neutrophil cytoplasmic antibody positivity: a case-control study. 2017 , 7, e015668		11
567	Akutes Nierenversagen bei immunologischen Systemerkrankungen. 2017 , 12, 338-344		
566	Renal-Limited "Lupus-Like" Nephritis: How Much of a Lupus?. 2017 , 7, 43-48		6
565	Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. 2017 , 96, e7429		19
564	Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. 2017 , 13, 483-495		142
563	Unraveling the podocyte injury in lupus nephritis: Clinical and experimental approaches. 2017 , 46, 632-641		15
562	Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus. 2017 , 26, 139-149		30

561	Anti-dsDNA antibodies and resident renal cells - Their putative roles in pathogenesis of renal lesions in lupus nephritis. 2017 , 185, 40-50	32
560	New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab. 2017 , 46, 788-790	20
559	Autoimmunity and Inflammation. 2017 , 1053-1090	
558	Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating mutations. 2018 , 15, 635-641	6
557	A clinico-pathological study of lupus nephritis based on the International Society of Nephrology-Renal Pathology Society 2003 classification system. 2017 , 9, 149-155	2
556	Glomerular Diseases. 2017 , 19-294.e1	
555	Urinary Albumin Levels are Independently Associated with Renal Lesion Severity in Patients with Lupus Nephritis and Little or No Proteinuria. 2017 , 23, 631-639	7
554	Systemic Lupus Erythematosus. 2017 , 235-267	1
553	Low copy number of FCGR3B is associated with lupus nephritis in a Chinese population. 2017 , 14, 4497-4502	3
552	Thrombotic thrombocytopenic purpura in the course of systemic lupus erythematosus in a 15-year-old girl. 2017 , 42, 407-408	3
551	Effects of age and gender on reference levels of biomarkers comprising the pediatric Renal Activity Index for Lupus Nephritis (p-RAIL). 2017 , 15, 74	12
550	Urine S100 proteins as potential biomarkers of lupus nephritis activity. 2017 , 19, 242	31
549	Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis. 2017 , 56, 1575-1580	1
548	Lupus Nephritis with Thymoma Managed by Thoracoscopic Surgery and Prednisolone. 2017 , 56, 3311-3316	
547	Comparison between disease onset patterns of Egyptian juvenile and adult systemic lupus erythematosus (single centre experience). 2018 , 27, 1039-1044	8
546	Renal outcomes in primary IgA nephropathy patients with segmental glomerular necrosis: a case-control study. 2018 , 75, 47-54	2
545	Early Renin-angiotensin System Blockade Improved Short-term and Longterm Renal Outcomes in Systemic Lupus Erythematosus Patients with Antiphospholipid-associated Nephropathy. 2018 , 45, 655-662	12
544	The Synergy of Endotoxin and (1- β)-D-Glucan, from Gut Translocation, Worsens Sepsis Severity in a Lupus Model of Fc Gamma Receptor IIb-Deficient Mice. 2018 , 10, 189-201	34

543	Kidney Function, CKD Causes, and Histological Classification. 2018 , 301-318	
542	Analysis of serum IL-38 in juvenile-onset systemic lupus erythematosus. 2018 , 28, 1069-1072	10
541	Full-house glomerular deposits: beware the sheep in wolf's clothing. <i>Kidney International</i> , 2018 , 93, 18-20.9	5
540	Podocyte and endothelial cell injury lead to nephrotic syndrome in proliferative lupus nephritis. 2018 , 72, 1084-1092	6
539	Serum IP-10 is useful for identifying renal and overall disease activity in pediatric systemic lupus erythematosus. 2018 , 33, 837-845	7
538	Systematic Review and the External Validity of Randomized Controlled Trials in Lupus Nephritis. 2018 , 3, 403-411	3
537	Blood pressure control over time in childhood-onset systemic lupus erythematosus. 2018 , 27, 657-664	6
536	Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis. 2018 , 21, 458-467	12
535	Identification and Management of Lupus Nephritis: An Overview. 2018 , 14, 1-6	2
534	Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. 2018 , 77, 1318-1325	63
533	A wolf in sheep's clothing. 2018 , 27, 1570-1571	
532	Spectrum of systemic lupus erythematosus in Oman: from childhood to adulthood. 2018 , 38, 1691-1698	5
531	Toll-Like Receptor 9 Deficiency Breaks Tolerance to RNA-Associated Antigens and Up-Regulates Toll-Like Receptor 7 Protein in Sle1 Mice. 2018 , 70, 1597-1609	8
530	Value of immunohistochemical expression of podocalyxin in active lupus nephritis. 2018 , 38, 64-72	1
529	Urinary TNF-like weak inducer of apoptosis (TWEAK) as a biomarker of lupus nephritis. 2018 , 77, 71-77	5
528	Utility of a repeat renal biopsy in lupus nephritis: a single centre experience. 2018 , 33, 507-513	10
527	Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men. 2018 , 27, 243-256	23
526	Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results. 2018 , 28, 85-94	4

525	Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. 2018 , 47, 545-551	28
524	Mesangial proliferative lupus nephritis with podocytopathy: a special entity of lupus nephritis. 2018 , 27, 303-311	13
523	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. 2018 , 70, 571-581	74
522	Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits. <i>Kidney International</i> , 2018 , 93, 214-220	9.9 13
521	Alpha beta double negative T cells in children with systemic lupus erythematosus: The relation to disease activity and characteristics. 2018 , 28, 654-660	6
520	Tubular basement membrane immune complex deposition is associated with activity and progression of lupus nephritis: a large multicenter Chinese study. 2018 , 27, 545-555	22
519	Low level of circulating basophil counts in biopsy-proven active lupus nephritis. 2018 , 37, 459-465	7
518	CD4 T helper cells and regulatory T cells in active lupus nephritis: an imbalance towards a predominant Th1 response?. 2018 , 191, 50-59	20
517	Worse renal outcome of subclass IV-G lupus nephritis patients over IV-S. 2018 , 27, 584-590	1
516	Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. 2018 , 21, 200-207	17
515	Oral supplementation of melatonin protects against lupus nephritis renal injury in a pristane-induced lupus mouse model. 2018 , 193, 242-251	15
514	[Lupus nephropathy: Insight in new treatments]. 2018 , 14, 1-12	
513	Interferon-inducible Mx1 protein is highly expressed in renal tissues from treatment-naïve lupus nephritis, but not in those under immunosuppressive treatment. 2018 , 28, 661-669	6
512	Value of immunohistochemical expression of podocalyxin in active lupus nephritis. 2018 , 38, 64-72	1
511	Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China. 2018 , 27, 389-398	3
510	Renal histology in Indigenous Australians with lupus nephritis. 2018 , 21, 194-199	3
509	Podocytopathy as the onset of systemic lupus erythematosus. 2018 , 38, 674-675	
508	Antiphospholipid Antibody Positivity and the Clinical Outcomes of Patients with Systemic Lupus Erythematosus. 2018 , 25, 239	3

507	Biopsy proven lupus nephritis in a black male patient in West Africa with systemic lupus erythematosus: case report. 2018 , 31, 198	1
506	Managing lupus nephritis: A guide for nurse practitioners. 2018 , 43, 43-48	0
505	Systemic Lupus Erythematosus: An Overview of the Disease Pathology and Its Management. 2018 , 10, e3288	10
504	Podocyte foot process width is a prediction marker for complete renal response at 6 and 12 months after induction therapy in lupus nephritis. 2018 , 197, 161-168	4
503	Dietary Docosahexaenoic Acid Prevents Silica-Induced Development of Pulmonary Ectopic Germinal Centers and Glomerulonephritis in the Lupus-Prone NZBWF1 Mouse. 2018 , 9, 2002	28
502	Glomerulonephritis in Animal Models and Human Medicine: Discovery, Pathogenesis, and Diagnostics. 2018 , 46, 898-903	2
501	Growing international evidence for urinary biomarker panels identifying lupus nephritis in children - verification within the South African Paediatric Lupus Cohort. 2018 , 27, 2190-2199	9
500	Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. 2018 , 16, 65	13
499	Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report. 2018 , 19, 276	6
498	Acute and Chronic Tubulointerstitial Nephritis of Rheumatic Causes. 2018 , 44, 619-633	13
497	Sequential renal biopsy in a patient with lupus nephritis and fingerprint deposits: a case report. 2018 , 2, 168-173	
496	Long-term effects of tacrolimus for maintenance therapy of lupus nephritis: a 5-year retrospective study at a single center. 2018 , 38, 2271-2277	6
495	Histological predictors of renal outcome in lupus nephritis: the importance of tubulointerstitial lesions and scoring of glomerular lesions. 2018 , 27, 1455-1463	25
494	Nephritis, cerebritis, and myositis after adalimumab therapy in a patient with rheumatoid arthritis: a case report. 2018 , 11, 151-154	1
493	Management and outcomes of pregnancy with or without lupus nephritis: a systematic review and meta-analysis. 2018 , 14, 885-901	18
492	A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. <i>Kidney International</i> , 2018 , 94, 788-794	9.9 56
491	Lupus nephritis pathology prediction with clinical indices. 2018 , 8, 10231	18
490	Composite urinary biomarkers to predict pathological tubulointerstitial lesions in lupus nephritis. 2018 , 27, 1778-1789	23

- 489 Lupus nephritis with massive subendothelial deposits in a patient with autoimmune hepatitis-related cirrhosis. **2018**, 13, 27-32
- 488 Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis-possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report. **2018**, 11, 165 6
- 487 Kollagenosen im Kindes- und Jugendalter. **2018**, 166, 562-571
- 486 Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis. **2018**, 37, 2399-2404 5
- 485 Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers. **2018**, 26, 1154-1165 17
- 484 The current role for clinical and renal histological findings as predictor for outcome in Australian patients with lupus nephritis. **2018**, 27, 1838-1846 9
- 483 Precision medicine in lupus nephritis: can biomarkers get us there?. **2018**, 201, 26-39 8
- 482 Podocytopathy as debut of a systemic lupus erythematosus. **2018**, 38, 674-675 1
- 481 NMR-Based Serum Metabolomics Reveals Reprogramming of Lipid Dysregulation Following Cyclophosphamide-Based Induction Therapy in Lupus Nephritis. **2018**, 17, 2440-2448 12
- 480 Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis. **2018**, 15, 5461-5468 1
- 479 Basophil involvement in lupus nephritis: a basis for innovation in daily care. **2019**, 34, 750-756 4
- 478 [Epidemiology of systemic lupus erythematosus in Reunion Island, Indian Ocean: A case-series in adult patients from a University Hospital]. **2019**, 40, 214-219 3
- 477 The Effect of Mycophenolate Mofetil on Non-Renal Manifestations in Systemic Lupus Erythematosus: Results from Korean Lupus Network Registry. **2019**, 34, e185 4
- 476 SerpinA3 in the Early Recognition of Acute Kidney Injury to Chronic Kidney Disease (CKD) transition in the rat and its Potentiality in the Recognition of Patients with CKD. **2019**, 9, 10350 14
- 475 Analysis of HLA-G expression in renal tissue in lupus nephritis: a pilot study. **2019**, 28, 1091-1100 2
- 474 Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia. **2019**, 28, 1082-1090 3
- 473 Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus. **2019**, 144, 106348 9
- 472 Differences in clinico-pathological characteristics and outcomes between proteinase 3-ANCA positivity and myeloperoxidase-ANCA positivity in lupus nephritis. **2019**, 28, 1111-1119 2

471	Complement alternative pathway activation associated with pulmonary hypertension in lupus nephritis patients. 2019 , 28, 1051-1061	1
470	TLR7 Protein Expression in Mild and Severe Lupus-Prone Models Is Regulated in a Leukocyte, Genetic, and IRAK4 Dependent Manner. 2019 , 10, 1546	7
469	Comparison of the Clinical Implications among Five Different Nutritional Indices in Patients with Lupus Nephritis. 2019 , 11,	5
468	SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus. 2019 , 9, 14433	11
467	The importance of tubuloreticular inclusions in lupus nephritis. 2019 , 51, 727-732	2
466	Membranous Lupus Nephritis: A Clinical Review. 2019 , 26, 393-403	14
465	Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice. 2019 , 158, 322-339	13
464	Immune Complexes Impaired Glomerular Endothelial Cell Functions in Lupus Nephritis. 2019 , 20,	4
463	KHA-CARI Guideline recommendations for renal biopsy. 2019 , 24, 1205-1213	11
462	Effect of mycophenolate and rapamycin on renal fibrosis in lupus nephritis. 2019 , 133, 1721-1744	10
461	Reversible cerebral vasoconstriction syndrome triggered by tacrolimus mimicked neuropsychiatric involvement in systemic lupus erythematosus. 2019 , 3, 119-123	
460	A patient with predominant interstitial nephritis as a renal manifestation of systemic lupus erythematosus. 2020 , 59, 685-687	1
459	Ultrasensitive serum interferon- β quantification during SLE remission identifies patients at risk for relapse. 2019 , 78, 1669-1676	30
458	Characteristics of lupus and lupus nephritis at a tertiary care center in Lebanon. 2019 , 28, 1598-1603	3
457	Rethinking Lupus Nephritis Classification on a Molecular Level. 2019 , 8,	8
456	Cost-effectiveness of tacrolimus for the treatment of moderate-to-severe lupus nephritis in China. 2019 , 8, 1125-1141	2
455	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. 2019 , 78, 634-640	35
454	Tomoelastography Paired With T2* Magnetic Resonance Imaging Detects Lupus Nephritis With Normal Renal Function. 2019 , 54, 89-97	16

453	Factors predictive of long-term mortality in lupus nephritis: a multicenter retrospective study of a Japanese cohort. 2019 , 28, 295-303		10
452	Development and Internal Validation of a Prediction Model to Estimate the Probability of Needing Aggressive Immunosuppressive Therapy With Cytostatics in de Novo Lupus Nephritis Patients. 2019 , 15, 27-33		
451	Urinary levels of the leukocyte surface molecule CD11b associate with glomerular inflammation in lupus nephritis. <i>Kidney International</i> , 2019 , 95, 680-692	9.9	11
450	Multiparameter diffusion-weighted imaging for characterizing pathological patterns in lupus nephritis patients: A preliminary study. 2019 , 50, 1075-1084		3
449	Disease presentation of 1312 childhood-onset systemic lupus erythematosus: influence of ethnicity. 2019 , 38, 2857-2863		10
448	Immunoglobulin Binding Protein 1 as a Potential Urine Biomarker in Patients with Lupus Nephritis. 2019 , 20,		7
447	The expression of NOD2, NLRP3 and NLRC5 and renal injury in anti-neutrophil cytoplasmic antibody-associated vasculitis. 2019 , 17, 197		9
446	Comparison of Renal Responses to Cyclophosphamide and Mycophenolate Mofetil used as Induction Therapies in Korean Patients with Lupus Nephritis. 2019 , 26, 57		2
445	Renal transplantation for lupus nephritis: non-adherence and graft survival. 2019 , 28, 651-657		3
444	Glomerular expression of matrix metalloproteinases in systemic lupus erythematosus in association with activity index and renal function. 2019 , 41, 229-237		4
443	Genetics and Autoimmunity. 2019 , 93-104		
442	Transmission electron microscopy. 2019 , 434-475		7
441	Association of anti-nucleosome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus. 2019 , 59, 10		3
440	Different histological classifications for Henoch-Schlelein purpura nephritis: which one should be used?. 2019 , 17, 10		28
439	Membranoproliferative Glomerulonephritis, Adult. 2019 , 403-419		
438	Clinical manifestations, immunological features and prognosis of Chinese pediatric systemic lupus erythematosus: A single-center study. 2019 , 22, 1070-1076		1
437	Role of syndecan-1 (CD138) in Egyptian systemic lupus erythematosus patients with lupus nephritis: Relation to disease activity. 2019 , 41, 289-294		
436	Not only disease activity but also chronic hypertension and overweight are determinants of pregnancy outcomes in patients with systemic lupus erythematosus. 2019 , 28, 529-537		2

435	Incidence and predictors of aorta calcification in patients with systemic lupus erythematosus. 2019 , 28, 275-282	3
434	The associations of endothelial and podocyte injury in proliferative lupus nephritis: from observational analysis to in vitro study. 2019 , 28, 347-358	6
433	Complete renal response at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study. 2019 , 28, 501-509	9
432	Conserved Disease Modules Extracted From Multilayer Heterogeneous Disease and Gene Networks for Understanding Disease Mechanisms and Predicting Disease Treatments. 2018 , 9, 745	46
431	Evaluation of a Novel Immunoassay for Quantification of C1q for Clinical Diagnostic Use. 2019 , 10, 7	12
430	Histopathology of Glomerular Diseases. 2019 , 43-58	
429	Overview of the Current Approach to Glomerular Disease Classification. 2019 , 59-85	1
428	Antibodies to M-type phospholipase A2 receptor (PLAR) in membranous lupus nephritis. 2019 , 28, 396-405	17
427	Lupus Podocytopathy: An Overview. 2019 , 26, 369-375	9
426	Classification of Lupus Nephritis; Time for a Change?. 2019 , 26, 323-329	6
425	Protocolo diagnóstico y tratamiento de la nefropatía lúpica. 2019 , 12, 4849-4852	
424	Sex differences in clinical presentation of systemic lupus erythematosus. 2019 , 10, 60	15
423	Syphilis and parvovirus B19 co-infection imitating a lupus nephropathy: A case report. 2019 , 98, e17040	5
422	Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus. 2019 , 34, 117-128	22
421	Addition of cyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy. 2019 , 47, 105-113	4
420	Pathogenesis of Lupus Nephritis. 2019 , 269-293	1
419	Epidemiology and Management of Lupus Nephritis. 2019 , 727-744	1
418	Decreased α nAChR mRNA levels in peripheral blood monocytes are associated with enhanced inflammatory cytokine production in patients with lupus nephritis. 2019 , 111, 359-366	4

417	How do lupus glomerulonephritis and its treatment affect the renal reserve?. 2019 , 51, 369-370		
416	A CD4 T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate. 2019 , 25, 75-81		105
415	Systemic lupus erythematosus: Diagnosis and clinical management. 2019 , 96, 1-13		175
414	Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. 2019 , 38, 859-867		12
413	Pediatric lupus nephritis. 2019 , 41, 252-265		14
412	Plasma sMer, sAxl and GAS6 levels correlate with disease activity and severity in lupus nephritis. 2019 , 49, e13064		9
411	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019 , 95, 281-295	9.9	87
410	Vitamin D protects podocytes from autoantibodies induced injury in lupus nephritis by reducing aberrant autophagy. 2019 , 21, 19		14
409	Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon- β . 2019 , 71, 756-765		28
408	Clinicopathological characteristics and renal outcomes of childhood-onset lupus nephritis with acute kidney injury: A multicenter study. 2019 , 29, 970-976		2
407	Discovery of SERPINA3 as a candidate urinary biomarker of lupus nephritis activity. 2019 , 58, 321-330		12
406	Development and Internal Validation of a Prediction Model to Estimate the Probability of Needing Aggressive Immunosuppressive Therapy With Cytostatics in de Novo Lupus Nephritis Patients. 2019 , 15, 27-33		5
405	Utility of urinary transferrin and ceruloplasmin in patients with systemic lupus erythematosus for differentiating patients with lupus nephritis. 2020 , 16, 17-23		8
404	Neutrophil to lymphocyte and platelet to lymphocyte ratios in systemic lupus erythematosus: Relation with disease activity and lupus nephritis. 2020 , 16, 255-261		17
403	Utility of urinary transferrin and ceruloplasmin in patients with systemic lupus erythematosus for differentiating patients with lupus nephritis. 2020 , 16, 17-23		2
402	Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics. 2020 , 35, 1721-1729		4
401	Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. <i>Kidney International</i> , 2020 , 97, 156-162	9.9	24
400	Idiopathic membranous nephropathy preceding membranous lupus nephritis: a case report. 2020 , 29, 340-343		

399	Clinical usefulness of anti-M-type phospholipase-A-receptor antibodies in patients with membranous nephropathy and the comparison of three quantification methods. 2020 , 43, 47-56	5
398	Comparison of lupus patients with early and late onset nephritis: a study in 71 patients from a single referral center. 2020 , 60, 5	2
397	Clinicopathological factors for tubulointerstitial injury in lupus nephritis. 2020 , 39, 1617-1626	6
396	Clinical characteristics and survival of 413 patients with systemic lupus erythematosus in southeastern areas of South Korea: A multicenter retrospective cohort study. 2020 , 23, 92-100	10
395	Utility of Genomic Testing after Renal Biopsy. 2020 , 51, 43-53	5
394	Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. 2020 , 29, 118-125	18
393	Renal microvascular lesions in lupus nephritis. 2020 , 42, 19-29	11
392	Value of monitoring urine ammonia at time of biopsy in patients with lupus nephritis. 2020 , 21, 442	1
391	Stellenwert der Nierenbiopsie bei Lupusnephritis. 2020 , 45, 319-327	1
390	Atrial thrombus as a complication of SLE and APS in an 8-year-old child. 2020 , 18, 90	0
389	Lupus nephritis: clinical presentations and outcomes in the 21st century. 2020 , 59, v39-v51	24
388	Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Systemic Lupus Erythematosus: Relation With Disease Activity and Lupus Nephritis. 2020 , 16, 255-261	1
387	Detection of water-molecular-motion configuration in patients with lupus nephritis: a primary study using diffusion-weighted imaging. 2020 , 21, 313	
386	Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. 2020 , 6,	7
385	/ABIN1 and lupus nephritis: review. 2020 , 7,	2
384	Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society. <i>Kidney International</i> , 2020 , 98, 1120-1134	9.9 15
383	Lupus nephritis. 2020 , 6, 7	127
382	A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. 2021 , 60, 3747-3759	9

381	CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis. 2021 , 36, 2256-2262	2
380	Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis. 2020 , 4, 67	4
379	Classifying and diagnosing systemic lupus erythematosus in the 21st century. 2020 , 59, v4-v11	23
378	Comparison of the 2018 and 2003 International Society of Nephrology/Renal Pathology Society classification in terms of renal prognosis in patients of lupus nephritis: a retrospective cohort study. 2020 , 22, 260	3
377	Histologic Case Definition of an Atypical Glomerular Immune-Complex Deposition Following Kidney Transplantation. 2020 , 5, 632-642	2
376	Uric acid and kidney damage in systemic lupus erythematosus. 2020 , 508, 197-205	8
375	Analysis of clinical and laboratory characteristics and pathology of lupus nephritis-based on 710 renal biopsies in China. 2020 , 39, 3353-3363	4
374	Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood. 2020 , 8, 205	4
373	Anti-complement factor H autoantibodies may be protective in lupus nephritis. 2020 , 508, 1-8	2
372	Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology. 2020 , 22, 122	7
371	Association of explanatory histological findings and urinary protein and serum creatinine levels at renal biopsy in lupus nephritis: a cross-sectional study. 2020 , 21, 208	2
370	Human cytomegalovirus pp65 peptide-induced autoantibodies cross-reacts with TAF9 protein and induces lupus-like autoimmunity in BALB/c mice. 2020 , 10, 9662	3
369	Circulating anti-C3b IgG in lupus nephritis: A large cohort study. 2020 , 217, 108514	1
368	Extranasal extranodal NK/T-cell lymphoma associated with systemic lupus erythematosus. 2020 , 112, 592-596	2
367	Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. 2020 , 79, 1077-1083	13
366	Small fiber neuropathy and related factors in patients with systemic lupus erythematosus; the results of cutaneous silent period and skin biopsy. 2020 , 60, 31	1
365	The α helix of TIRAP holds therapeutic potential in TLR-mediated autoimmune diseases. 2020 , 245, 119974	10
364	Curcumin Attenuates Both Acute and Chronic Immune Nephritis. 2020 , 21,	10

363	Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study. 2020 , 35, 1235-1246	7
362	Interleukin-34 as a marker for subclinical proliferative lupus nephritis. 2020 , 29, 607-616	3
361	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. 2020 , 79, 713-723	173
360	The Various Forms of Nephrotic Syndrome in a Patient with Systemic Lupus Erythematosus. 2020 , 2020, 7869216	1
359	Dysregulation of cell-free long non-coding RNAs (NEAT2, CTC-471J1.2 and lnc-DC) in Egyptian systemic lupus and lupus nephritis patients. 2020 , 24, 100665	2
358	The predictive value of crescents in the disease progression of lupus nephritis based on the 2018 International Society of Nephrology/Renal Pathology Society Revision System: a large cohort study from China. 2020 , 42, 166-172	4
357	Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the Attikon Cohort. 2020 , 29, 514-522	17
356	Angiotensin II receptor agonist antibodies are associated with microvascular damage in lupus nephritis. 2020 , 29, 371-378	8
355	Deep Phenotyping of Urinary Leukocytes by Mass Cytometry Reveals a Leukocyte Signature for Early and Non-Invasive Prediction of Response to Treatment in Active Lupus Nephritis. 2020 , 11, 256	8
354	Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?. 2020 , 47, 1366-1373	3
353	Long-term Safety and Effectiveness of Tacrolimus in Patients With Lupus Nephritis: 5-year Interim Postmarketing Surveillance Study in Japan (TRUST). 2021 , 48, 74-81	5
352	Differentiation of Bilayer Interventricular Septum Function in Children with Systemic Lupus Erythematosus by Tissue Doppler and Speckle Tracking Imaging. 2021 , 38, 16-24	1
351	Management of Severe Refractory Systemic Lupus Erythematosus: Real-World Experience and Literature Review. 2021 , 60, 17-30	4
350	Kidney outcomes for children with lupus nephritis. 2021 , 36, 1377-1385	16
349	Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. 2021 , 27, 152-171	6
348	What is the value of repeat kidney biopsies in patients with lupus nephritis?. 2021 , 30, 25-34	1
347	Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis. 2021 , 40, 1853-1859	2
346	Urinary sediments could differentiate endocapillary proliferative lupus nephritis and endocapillary proliferative IgA nephropathy. 2021 , 90, 107122	1

345	Life prognosis and renal relapse after induction therapy in Japanese patients with proliferative and pure membranous lupus nephritis. 2021 , 60, 2333-2341	3
344	Serum uric acid as a predictor for nephritis in Egyptian patients with systemic lupus erythematosus. 2021 , 30, 378-384	2
343	Detection of renal hypoxia configuration in patients with lupus nephritis: a primary study using blood oxygen level-dependent MR imaging. 2021 , 46, 2032-2044	2
342	Milk fat globule epidermal growth factor 8 (MFG-E8) on monocytes is a novel biomarker of disease activity in systemic lupus erythematosus. 2021 , 30, 61-69	2
341	Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis. 2021 , 73, 244-254	6
340	High Burden of Premature Arteriosclerosis on Renal Biopsy Results in Incident Lupus Nephritis. 2021 , 73, 394-401	0
339	Systemic lupus erythematosus in children. 2021 , 365-380	
338	Longitudinal growth patterns and final height in childhood-onset systemic lupus erythematosus. 2021 , 180, 1431-1441	2
337	Anti-NuMA antibodies: clinical associations and significance in patients with primary Sjögren's syndrome or systemic lupus erythematosus. 2021 , 60, 4074-4084	1
336	Electron microscopy study of 496 cases of lupus nephritis: A single-center experience. 2021 , 30, 587-596	
335	Membranoproliferative-like IgA vasculitis nephritis in children: report of two cases. 2021 ,	
334	Relation between Vitamin D Level and Cyclin-Dependent Kinase-1 Gene Expression in Egyptian Patients with Lupus Nephritis and their Impact on Disease Activity. 2021 , 31, 163-168	
333	The ISN/RPS 2016 classification predicts renal prognosis in patients with first-onset class III/IV lupus nephritis. 2021 , 11, 1525	5
332	Renale Manifestationen bei systemischen Autoimmunerkrankungen. 2021 , 16, 81-90	
331	Systemic Lupus Erythematosus. 2021 , 133-141	
330	Histological distribution pattern of hemosiderin deposition on the chorionic plate and fetal membrane of diffuse chorioamniotic hemosiderosis related to chronic abruption oligohydramnios sequence. 2021 , 105, 1-6	
329	A Fatal Case of Diffuse Alveolar Hemorrhage in the Setting of Systemic Lupus Erythematosus: A Case Report and Review of Noninfectious Causes of Acute Pulmonary Hemorrhage in Adults. 2021 , 2021, 6620701	1
328	Downregulated Serum Exosomal miR-451a Expression Correlates With Renal Damage and Its Intercellular Communication Role in Systemic Lupus Erythematosus. 2021 , 12, 630112	8

327	Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis. 2021 , 8,	3
326	Automated Computational Detection of Interstitial Fibrosis, Tubular Atrophy, and Glomerulosclerosis. 2021 ,	12
325	Selective immunoglobulin M deficiency complicated by systemic lupus erythematosus and antiphospholipid syndrome: a case report and review of literature. 2021 , 10, 435-441	
324	Kidney Level Lupus Nephritis Classification Using Uncertainty Guided Bayesian Convolutional Neural Networks. 2021 , 25, 315-324	6
323	Management of Lupus Nephritis. 2021 , 10,	3
322	Atualizaçã terapêutica no LES juvenil [nefrite]. 2021 , 6-15	
321	Retrospective analysis of clinical and pathomorphological features of lupus nephritis in children. 2021 , 66, 128-137	
320	Circulating miR-181a and miR-223 expression with the potential value of biomarkers for the diagnosis of systemic lupus erythematosus and predicting lupus nephritis. 2021 , 23, e3326	3
319	Case Report: Kidney Transplantation in a Patient With Acquired Agammaglobulinemia and SLE. Issues and Challenges. 2021 , 8, 665475	
318	Towards harmony in defining and reporting glomerular diseases on kidney biopsy. 2021 , 30, 280-286	
317	Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study. 2021 , 60, 5134-5141	2
316	Glutathione S-transferase, catalase, and mitochondrial superoxide dismutase gene polymorphisms modulate redox potential in systemic lupus erythematosus patients from Manaus, Amazonas, Brazil. 2021 , 40, 3639-3649	0
315	Genetic Variant CFH rs6677604 Might Play a Protective Role in lupus Nephritis. 2021 , 361, 336-343	
314	Intra-body dynamics of D-serine reflects the origin of kidney diseases. 2021 , 25, 893-901	2
313	Chronic exposure to PM2.5 aggravates SLE manifestations in lupus-prone mice. 2021 , 18, 15	1
312	Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. 2021 ,	1
311	Interleukin-12 exacerbates symptoms in an MRL/MpJ-Faslpr mouse model of systemic lupus erythematosus. 2021 , 21, 627	0
310	Systemic lupus erythematosus in children and adults: A retrospective study in Brazilian patients. 2021 , 30, 1197-1202	1

309	Sustained high expression of multiple APOBEC3 cytidine deaminases in systemic lupus erythematosus. 2021 , 11, 7893	2
308	Diagnostic significance of circulating miR-485-5p in patients with lupus nephritis and its predictive value evaluation for the clinical outcomes. 2021 , 84, 491-497	3
307	Renal Biopsy in Children-Effect on Treatment Decisions: A Single-Center Experience. 2021 , 88, 1036-1039	4
306	Is podocytopathy another image of renal affection in p-SLE?. 2021 , 19, 57	1
305	Using MEST-C Scores and the International Study of Kidney Disease in Children Classification to Predict Outcomes of Henoch-Schönlein Purpura Nephritis in Children. 2021 , 9, 658845	0
304	Frequency of anti-neutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus. 2021 ,	
303	Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. 2021 , 10,	3
302	Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity. 2021 , 26, 443-449	2
301	Role of clinicopathological features for the early prediction of prognosis in lupus nephritis. 2021 , 69, 285-294	0
300	Lupus-like membranous nephropathy. Is it lupus? Report of 5 cases in a reference hospital in Mexico. 2021 , 30, 1347-1357	0
299	Urine β -glycoprotein 1 as a biomarker for diagnosis of systemic lupus erythematosus. 2021 , 30, 1306-1313	1
298	LONG TERM RENAL SURVIVAL OF PEDIATRIC PATIENTS WITH LUPUS NEPHRITIS. 2021 ,	1
297	Hydroxychloroquine use and blood pressure below 130/80 are associated with remission in lupus nephritis: A cohort study. 2021 , 28, 109-109	
296	Clinical and laboratory features, disease activity, and outcomes of juvenile systemic lupus erythematosus at diagnosis: a single-center study from southern China. 2021 , 40, 4545-4552	1
295	Distribution pattern of mesangial C4d deposits as predictor of kidney failure in IgA nephropathy. 2021 , 16, e0252638	1
294	Immune-Related Urine Biomarkers for the Diagnosis of Lupus Nephritis. 2021 , 22,	4
293	The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients. 2021 , 12, 654652	3
292	Molecular Signatures of Kidney Antibody-Secreting Cells in Lupus Patients With Active Nephritis Upon Immunosuppressive Therapy. 2021 , 73, 1461-1466	6

291	The relationship between the modified National Institute of Health activity and chronicity scoring system, and the long-term prognosis for lupus nephritis: A retrospective single-center study. 2021 , 30, 1739-1746	1
290	The immunoregulatory axis (programmed death-1/programmed death ligand-1) on CD4+ T cells in lupus nephritis: association with vitamin D and chemokine C-X-C motif ligand 12. 2021 , 65, 392-399	0
289	Autoantibody Profile of Egyptian Juvenile Systemic Lupus Erythematosus Patients and Its Association with Clinical Characteristics and Disease Activity. 2021 , 13, 201-212	
288	Cf-02, a novel benzamide-linked small molecule, blunts NF- κ B activation and NLRP3 inflammasome assembly and improves acute onset of accelerated and severe lupus nephritis in mice. 2021 , 35, e21785	1
287	The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes. 2021 , 6, 1977-1980	3
286	Lupus Nephritis: The Significant Contribution of Electron Microscopy. 1-25	1
285	Acuerdo entre biopsia y función renal en pacientes pediátricos con nefritis lúpica. Un estudio retrospectivo. 2021 ,	
284	Altered expression of genes controlling metabolism characterizes the tissue response to immune injury in lupus. 2021 , 11, 14789	5
283	[21/F-Arthralgia and skin lesions : Preparation for the medical specialist examination: part 79]. 2021 , 62, 519-525	
282	Clinical and Genetic Risk Factors Associated With the Presence of Lupus Nephritis. 2021 , 28, 150-158	1
281	Evolving fuzzy k-nearest neighbors using an enhanced sine cosine algorithm: Case study of lupus nephritis. 2021 , 135, 104582	10
280	Lupus Nephritis: Current Updates.	
279	Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis. 2021 , 1	1
278	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. 2021 , 8,	0
277	First Diagnosis of Systemic Lupus Erythematosus in Hospitalized Patients: Clinical Phenotypes and Pitfalls for the Non-Specialist. 2021 ,	1
276	[Spontaneous intracranial hypotension: A rare cause of headache in systemic lupus erythematosus]. 2021 , 42, 571-574	1
275	Not all that is full house is systemic lupus erythematosus: a case of membranous nephropathy due to syphilis infection. 2021 , 14,	1
274	Microarray-based analysis of renal complement components reveals a therapeutic target for lupus nephritis. 2021 , 23, 223	4

273	Comparison of Renal Responses Between Continuous Mycophenolate Mofetil and Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Lupus Nephritis. 2021 ,		0
272	Low Urine Secretion of Semaphorin3A in Lupus Patients with Proteinuria. 2021 , 1		
271	A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. <i>Kidney International</i> , 2021 ,	9.9	9
270	Autoimmune-mediated renal disease and hypertension. 2021 , 135, 2165-2196		1
269	Antidiabetic effects of hydroxychloroquine in two Japanese patients with systemic lupus erythematosus.. 2022 , 13, 447-451		
268	Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study. 2021 , 12, 756941		1
267	EuroLupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. 2021 , 20, 102898		1
266	Literatur. 2021 , 653-661		
265	Autoimmune disorders. 2021 , 777-826		
264	Association of coexisting anti-ribosomal P and anti-dsDNA antibodies with histology and renal prognosis in lupus nephritis patients. 2021 , 30, 448-458		1
263	Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa. 2021 , 53, 1865-1873		0
262	Renal Arteriosclerosis Strongly Associated Atherosclerotic Cardiovascular Disease Risk in Lupus Nephritis. 2021 ,		
261	Diagnostic Utility of Galactose-Deficient Immunoglobulin A1 Immunostaining in the Differentiation of Lupus Nephritis and Immunoglobulin A Nephropathy. 2021 , 1, 34-39		
260	Anti-Nuclear Antibody-Negative Lupus Nephritis or Post-Infectious Glomerulonephritis: Diagnostic Dilemma in a Young Male. 2021 , 31, 394-397		0
259	Albumin-to-globulin ratio (AGR) as a potential marker of predicting lupus nephritis in Chinese patients with systemic lupus erythematosus. 2021 , 30, 412-420		3
258	Kidney disease. 2021 , 471-502		
257	Glomeruläre Erkrankungen. 2017 , 69-123		1
256	Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus. 2010 , 20, 168-77		6

255	Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus. 2010 , 20, 291-4	7
254	High circulating levels of interleukin-18 binding protein indicate the severity of glomerular involvement in systemic lupus erythematosus. 2012 , 22, 73-9	6
253	Clinical features of systemic lupus erythematosus. 2011 , 1229-1246.e5	2
252	Clinical features of systemic lupus erythematosus. 2015 , 1032-1044	7
251	Clinical Features and Treatment of Systemic Lupus Erythematosus. 2009 , 1263-1300	4
250	Urinary Cellular Profile as a Biomarker for Lupus Nephritis. 2021 , 27, e469-e476	3
249	Podocyte involvement in human immune crescentic glomerulonephritis. <i>Kidney International</i> , 2005 , 68, 1109-19	9.9 59
248	Intracapillary immune complexes recruit and activate slan-expressing CD16+ monocytes in human lupus nephritis. 2018 , 3,	19
247	Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis. 2019 , 129, 2251-2265	31
246	CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease. 2018 , 128, 3445-3459	47
245	Deficiency of activating Fc γ receptors reduces hepatic clearance and deposition of IC and increases CIC levels in mercury-induced autoimmunity. 2010 , 5, e13413	8
244	Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. 2013 , 8, e60493	36
243	Retrospective Study of Phospholipase A2 Receptor and IgG Subclasses in Glomerular Deposits in Chinese Patients with Membranous Nephropathy. 2016 , 11, e0156263	27
242	Silica-Triggered Autoimmunity in Lupus-Prone Mice Blocked by Docosahexaenoic Acid Consumption. 2016 , 11, e0160622	22
241	PLA2R antibody, PLA2R rs4664308 polymorphism and PLA2R mRNA levels in Tunisian patients with primary membranous nephritis. 2020 , 15, e0240025	2
240	The utility of urinary biomarker panel in predicting renal pathology and treatment response in Chinese lupus nephritis patients. 2020 , 15, e0240942	3
239	An Overlapping Case of Lupus Nephritis and IgG4-Related Kidney Disease. 2015 , 7, 575-81	10
238	Re-biopsy in lupus nephritis. 2015 , 133, 162-3	1

237	[Successful treatment of early intervention with tacrolimus for a patient with lupus nephritis III+V]. 2008 , 31, 460-4	3
236	Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis. 2019 , 71, 4-11	4
235	2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. 2020 , 1, 5-23	4
234	Urinary lipoxin A4 as a biomarker for systemic lupus erythematosus. 2015 , 42, 55-61	3
233	Update on the etiology, classification, and management of glomerular diseases. 2020 , 10, 61-67	1
232	Correlation of serum interleukin-10 level with disease activity and severity in systemic lupus erythematosus. 2018 , 45, 25-33	7
231	Mycophenolate versus Cyclophosphamide for Lupus Nephritis. 2018 , 28, 35-40	14
230	Urinary soluble alpha chain of the interleukin-2 receptor as a biomarker of active lupus nephritis in Egyptian children with juvenile systemic lupus erythematosus. 2021 , 36, 47-55	1
229	Clinical and autoantibody profile in male and female patients with systemic lupus erythematosus: A retrospective study in 603 Brazilian patients. 2020 ,	3
228	Glomerulonephritis with crescents in children: etiology and predictors of renal outcome. 2011 , 2011, 507298	7
227	From Skin to Kidneys: Cutaneous Clues of Renal Disease in Children. 2020 , 10, e2020095	1
226	Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. 2009 , 133, 233-48	70
225	A proposed histopathologic classification, scoring, and grading system for renal amyloidosis: standardization of renal amyloid biopsy report. 2010 , 134, 532-44	34
224	History of Proliferative Glomerulonephritis Predicts End Stage Kidney Disease in Pure Membranous Lupus Nephritis. 2021 ,	0
223	Urine and serum interleukin 35 as potential biomarkers of lupus nephritis. 2021 , 46, 351-359	
222	Comparison of renal remission and relapse-free rate in initial- and delayed-onset lupus nephritis. 2021 , 24, 1500-1509	
221	The lupus nephritis management renaissance. <i>Kidney International</i> , 2021 ,	9.9 8
220	?????14?????????????????. 2005 , 18, 127-130	

- 219 Kidney Disease: Goodpasture's Disease, Lupus Nephritis, ANCA-Associated Glomerulonephritis. **2006**, 821-840
- 218 Glomerular, Vascular, and Tubulo-Interstitial Diseases. **2008**, 237-285
- 217 [Systemic lupus erythematosus and pregnancy]. **2008**, 149, 723-31
- 216 Glomerular Clinicopathologic Syndromes. **2009**, 148-159 3
- 215 Glomerulonephritis. **2009**, 991-998
- 214 RENAL PATHOLOGY. **2010**, 1-101 1
- 213 The gene expression of NGAL and TLR9 in glomerulus and tubulo-interstitium of patients with lupus nephritis. **2011**, 02, 33-39
- 212 Secondary Glomerular Disease. **2011**, 1192-1277
- 211 The kidney and rheumatic disease. **2011**, 329-345.e3
- 210 OX40/OX40L in Systemic Lupus Erythematosus: Association with Disease Activity and Lupus Nephritis. **2011**, 31, 29-34 1
- 209 Autoimmune Diseases. **2011**, 763-794.e8 1
- 208 A proposed histopathologic classification, scoring, and grading system for renal amyloidosis. **2011**, 135, 168; author reply 168-9
- 207 Collagen Vascular Diseases. **2012**, 994-1013
- 206 Lupus Nephritis. **2012**, 2773-2788
- 205 Glomerular Diseases. **2012**, 1-301 0
- 204 Cutaneous Findings of Collagen Vascular Disease and Related Emergent Complications. **2013**, 207-234
- 203 Hidden face of lupus nephritis exposed: Isolated tubulointerstitial lupus nephritis. **2013**, 2, 71-2 4
- 202 SLE in pregnancy: lupus nephritis flare or pre-eclampsia? diagnostic challenge. **2015**, 177-190

- 201 Clinical Significance of Renal Interstitial Fibrosis in Patients with Lupus Nephritis. **2015**, 61, 418-425
- 200 The kidney and rheumatic disease. **2015**, 286-297
- 199 A novel role of peptidyl-prolyl isomerase-1 as inducer of IL-6 expression in systemic lupus erythematosus. **2015**, 3, 439-450
- 198 Acute Glomerular Diseases in Children. **2015**, 8, 104-116
- 197 Lupus Nephritis. **2016**, 759-780
- 196 Lupus-like Glomerulonephritis Associated with Extranodal Marginal Zone B-cell Lymphoma of MALT. **2016**, 90, 50-54
- 195 Tools for Renal Tissue Analysis. **2016**, 151-163
- 194 Differences of Histological Classification Between the Japanese Histological Grade Classification and the Oxford Classification. **2016**, 69-87
- 193 Differential Diagnosis: Lupus Nephritis and IgG4-Related Kidney Disease. **2016**, 279-289
- 192 <i>Staphylococcus</i>-associated Glomerulonephritis. **2016**, 90, 148-153
- 191 Rapidly Progressive Glomerulonephritis Associated with Systemic Lupus Erythematosus. 028-031
- 190 Overview of the Current Approach to Glomerular Disease Classification. **2017**, 1-28
- 189 Rheumatologie. **2017**, 469-497
- 188 Membranoproliferative Glomerulonephritis, Adult. **2017**, 1-16
- 187 Disease manifestations. **2018**, 39-70
- 186 Disease classification. **2018**, 27-37
- 185 Histopathology of Glomerular Diseases. **2018**, 1-16
- 184 General principles in the treatment of lupus nephritis with the prevention of cardiovascular events. **2018**, 12, 4-8

- 183 Lupus Flare in Pregnancy. **2019**, 53, 48-59
- 182 Management of patients with systemic lupus erythematosus in real clinical practice. **2019**, 57, 191-196 4
- 181 Systemic Lupus Erythematosus. **2020**, 537-541
- 180 Management of Lupus Nephritis in Children. **2020**, 57, 401-406 1
- 179 Factors Associated with Renal Outcomes in an Inception Cohort of Biopsy-proven Lupus Nephritis Patients. **2020**, 20, 9-20
- 178 Impact of Consensus Definitions on Identification of Glomerular Lesions by Light and Electron Microscopy.. **2022**, 7, 78-86 0
- 177 Deep Learning-Based Artificial Intelligence System for Automatic Assessment of Glomerular Pathological Findings in Lupus Nephritis. **2021**, 11, 2
- 176 75-Year-Old Man With Fever and Malaise. **2021**, 96, 2905-2910
- 175 Nierenversagen im Rahmen von autoimmunen Systemerkrankungen. **2020**, 40, 401-406
- 174 Urinary podocalyxin: Is it a real index of disease activity in egyptian patients lupus nephritis?. **2020**, 31, 1198-1205
- 173 Recurrent Glomerulonephritis in the Kidney Allograft. **2020**, 30, 359-369 0
- 172 Serum Cystatin C Measurement in Lupus Nephritis Patients: Its Correlation with Clinical and Histopathological Findings. **2020**, 2, 35-42 0
- 171 Agreement between biopsy and renal function in pediatric patients with lupus nephritis. A retrospective study. **2021**,
- 170 Beyond ISN/RPS Lupus Nephritis Classification: Adding Chronicity Index to Clinical Variables Predicts Kidney Survival.. **2022**, 3, 122-132 0
- 169 The Economic Burden of Lupus Nephritis: A Systematic Literature Review. **2021**, 1 3
- 168 CCR2- and CCR5-mediated macrophage infiltration contributes to glomerular endocapillary hypercellularity in antibody-induced lupus nephritis. **2021**, 0
- 167 LUPUS: Trends of the disease in Northwest Punjab. 2, 36-41
- 166 Pulmonary hemorrhage, due to rupture of small muscular arteries, in an autopsy case of systemic lupus erythematosus with antiphospholipid antibodies. **2008**, 18, 529-31

- 165 Antiribosomal-P protein antibodies are associated with proliferative glomerulonephritis more strongly than with membranous glomerulonephritis in Japanese patients with systemic lupus erythematosus. **2012**, 22, 488-90 1
- 164 Glucocorticoid Withdrawal in Lupus Nephritis: A Study Protocol and Literature Review. **2020**, 20, 47-55
- 163 The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part I. **2020**, 14, 7-15
- 162 Conference report--lupus nephritis: diagnosis, therapy, and outcomes. **2004**, 6, 23 1
- 161 Childhood-onset systemic lupus erythematosus. **2007**, 99, 777-84 12
- 160 25-year-old man with flank pain, hematuria, and proteinuria. **2009**, 84, 72-5
- 159 Mouse models of membranous nephropathy: the road less travelled by. **2013**, 2, 135-45 13
- 158 A treatment algorithm for children with lupus nephritis to prevent developing renal failure. **2014**, 5, 250-5 2
- 157 Clinical features and mortality in Chinese with lupus nephritis and neuropsychiatric lupus: A 124-patient study. **2014**, 19, 414-9 6
- 156 Podocyte-associated mRNA profiles in kidney tissue and in urine of patients with active lupus nephritis. **2015**, 8, 4600-13 12
- 155 Glomerular necrotic lesions and long-term outcomes among patients with proliferative lupus nephritis. **2015**, 8, 5787-92 2
- 154 Association of miRNA-145 expression in vascular smooth muscle cells with vascular damages in patients with lupus nephritis. **2015**, 8, 12646-56 6
- 153 Lupus nephritis in Bangladesh: unfolding the story. **2016**, 5, 26-27
- 152 Immune response against the coiled coil domain of Sjögren's syndrome associated autoantigen Ro52 induces salivary gland dysfunction. **2018**, 36 Suppl 112, 41-46 6
- 151 Induction therapy downregulates the expression of Th17/Tfh cytokines in patients with active lupus nephritis. **2018**, 7, 67-75 2
- 150 [Pregnancy outcome in a woman with premature ovarian insufficiency complicated by systemic lupus erythematosus during pregnancy: a case report]. **2017**, 37, 1683-1687
- 149 Metabolomics approach reveals urine biomarkers and pathways associated with the pathogenesis of lupus nephritis. **2019**, 22, 1288-1295 5
- 148 Effects of alternative remission criteria on outcome of pediatric proliferative lupus nephritis: a multi-center retrospective study of pediatric proliferative lupus nephritis. **2021**, 13, 4510-4520

- 147 Full-house nephropathy associated with high expression of SPATA5L1 due to a genetic pathogenic variant. **2021**, 0
- 146 Renal function deterioration is an independent mortality determinant in Koreans diagnosed with lupus nephritis. **2021**, 30, 1896-1905 1
- 145 Fecal microbiota changes in NZB/W F1 mice after induction of lupus disease. **2021**, 11, 22953 0
- 144 Treatment of Lupus Nephritis from Iranian Traditional Medicine and Modern Medicine Points of View: A Comparative Study. **2021**, 2021, 6645319
- 143 Retrospective review of the clinical and laboratory data in silent lupus nephritis. **2021**, 1
- 142 Revisiting Vasculopathy in Lupus Nephritis: A Renal Biopsy Evaluation Study.. **2022**, 32, 28-33 0
- 141 Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial.. **2021**, 70, 103324 1
- 140 Systemischer Lupus erythematodes. **2015**, 1-13
- 139 A 4-year old presenting with fever and achiness. **2021**, 9, 2050313X211056416
- 138 B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. **2021**, 19
- 137 Glucocorticoid discontinuation in pediatric-onset systemic lupus erythematosus: a single-center experience.. **2022**, 1 0
- 136 Understanding the Gut-Kidney Axis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: An Analysis of Gut Microbiota Composition.. **2022**, 13, 783679 0
- 135 Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus.. **2022**, 0
- 134 MicroRNA-30a Targets Notch1 to Alleviate Podocyte Injury in Lupus Nephritis.. **2022**, 1-13
- 133 High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership.. **2022**,
- 132 Proximal Renal Tubular Acidosis (Type II). **2022**, 101-109
- 131 A Contemporary Update on the Diagnosis of Systemic Lupus Erythematosus.. **2022**, 1 0
- 130 The Shifting Landscape of Lupus Nephritis Management: A Review.. **2022**, 14, e20950 0

129	Anti-DFS70 Antibodies Are Associated With Proliferative Lupus Nephritis and Renal Pathological Activity.. 2022 , 13, 810639	0
128	Longitudinal analysis of urinary proteins in lupus nephritis - A pilot study.. 2022 , 236, 108948	0
127	An efficient multilevel thresholding image segmentation method based on the slime mould algorithm with bee foraging mechanism: A real case with lupus nephritis images.. 2021 , 142, 105179	5
126	Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.. 2022 ,	8
125	Uncovering Molecular Heterogeneity in the Kidney With Spatially Targeted Mass Spectrometry.. 2022 , 13, 837773	2
124	Ocular manifestations and full house membranous nephropathy as a rare presentation of secondary syphilis.. 2022 , 28, e01461	0
123	Silica-associated systemic lupus erythematosus with lupus nephritis and lupus pneumonitis: A case report and a systematic review of the literature.. 2022 , 101, e28872	
122	Chronic kidney disease in Korean patients with lupus nephritis: over a 35-year period at a single center.. 2022 , 1	
121	Association of Health Literacy and Numeracy with Lupus Knowledge and the Creation of the Lupus Knowledge Assessment Test (LKAT).. 2022 ,	0
120	Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial.. 2022 , 5, e224492	1
119	The Role of Parietal Epithelial Cells in the Pathogenesis of Podocytopathy.. 2022 , 13, 832772	1
118	Lower socioeconomic status worsens outcome of patients with systemic lupus erythematosus independently of access to healthcare.. 2022 , 9612033221084518	1
117	The spectrum of renal diseases with lupus-like features: a single-center study.. 2022 , 44, 581-593	0
116	Renal and Inflammatory Proteins as Biomarkers of Diabetic Kidney Disease and Lupus Nephritis.. 2022 , 2022, 5631099	1
115	The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus.. 2022 , 9612033221086123	
114	Multidisciplinary Lupus Nephritis Clinic Reduces Time to Renal Biopsy and Improves Care Quality.. 2022 ,	
113	Measurement of anti-suprabasin antibodies, multiple cytokines and chemokines as potential predictive biomarkers for neuropsychiatric systemic lupus erythematosus.. 2022 , 237, 108980	1
112	Lupus nephritis diagnosis using enhanced moth flame algorithm with support vector machines.. 2022 , 145, 105435	2

- 111 Clinical relevance of glomerular IgM deposition in patients with lupus nephritis. **2021**, 22, 75 o
- 110 Effect of sera from lupus patients on the glomerular endothelial fibrinolysis system.. **2021**, 64, e15099
- 109 Tribute to Jan Weening (1950-2022). *Kidney International*, **2022**, 101, 840-842 9.9
- 108 Non-neoplastic renal diseases. 2203-2253
- 107 Data_Sheet_1.pdf. **2019**,
- 106 Data_Sheet_1.pdf. **2020**,
- 105 Table_1.XLSX. **2019**,
- 104 Table_2.XLSX. **2019**,
- 103 Table_3.XLSX. **2019**,
- 102 Table_4.XLSX. **2019**,
- 101 Data_Sheet_1.docx. **2019**,
- 100 Table_1.PDF. **2018**,
- 99 Table_2.PDF. **2018**,
- 98 Table_3.PDF. **2018**,
- 97 Table_4.PDF. **2018**,
- 96 Table_5.PDF. **2018**,
- 95 Table_6.PDF. **2018**,
- 94 Transcriptome Studies in Lupus Nephritis.. **2022**, 70, 15

93	Proteomic profiling of kidney samples in patients with pure membranous and proliferative lupus nephritis.. 2022 , 9612033221094711	0
92	OUP accepted manuscript.	1
91	Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.. 2022 , 2072143	1
90	Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis.. 2022 , 9,	0
89	Frequency of anti-neutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus. 2022 , 29, 107-112	
88	Renal Pathology. 2022 , 111-149	
87	Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis. 13,	1
86	Long-Term Kidney Prognosis and Pathological Characteristics of Late-Onset Lupus Nephritis. 2022 , 9,	
85	Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience. 096120332211063	
84	When the Illness Has No Name: Focus on Clinical Trials in Systemic Lupus Erythematosus. 2022 , 125-131	
83	Deep Learning-Based Model Significantly Improves Diagnostic Performance for Assessing Renal Histopathology in Lupus Glomerulonephritis. 2022 , 336-345	1
82	Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. annrheumdis-2022-222435	0
81	Characteristics and renal survival of patients with lupus nephritis with glomerular immunoglobulin G4 deposition: a single-centre retrospective analysis. 2022 , 9, e000690	
80	A Histology-Guided Approach to the Management of Patients with Lupus Nephritis: Are We There Yet?. 2022 , 10, 1409	1
79	Characteristics and Outcomes of a Hispanic Lupus Nephritis Cohort from Mexico.	0
78	Urinary Serpin-A3 is an early predictor of clinical response to therapy in patients with proliferative Lupus Nephritis.	
77	Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study. 2022 , 24,	0
76	Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target. 2022 , 102861	0

- 75 Urine inter-alpha-trypsin inhibitor family-related proteins may serve as biomarkers for disease activity of lupus.
- 74 Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria. **2022**, 17, 1150-1158
- 73 Could systemic immune inflammation index be a new parameter for diagnosis and disease activity assessment in systemic lupus erythematosus?
- 72 Severe lupus nephritis in the present days. 2,
- 71 Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares, and enrich clinical trials in lupus. Publish Ahead of Print,
- 70 Klassifikation der Lupusnephritis.
- 69 Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III/IV. *annrheumdis-2022-222620*
- 68 Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis. **2022**, 9, e000721
- 67 Good Long-Term Prognosis of Lupus Nephritis in the High-Income Afro-Caribbean Population of Martinique with Free Access to Healthcare. **2022**, 11, 4860
- 66 Lupus nephritis: new progress in diagnosis and treatment. **2022**, 102871
- 65 Anxiety and depression prevalence and their risk factors in lupus nephritis patients: A case-control study. **2022**, 10,
- 64 Lupus nephritis in the XXI century. **2022**, 94, 713-717
- 63 Renal and vascular outcomes in patients with isolated antiphospholipid syndrome nephropathy. **2022**, 132, 102889
- 62 Successful Discontinuation of Glucocorticoid Treatment after Administration of a Calcineurin Inhibitor for Nephrotic Syndrome in a Patient With Lupus Nephritis: A Case Report. **2022**,
- 61 Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort. **2022**, 9, e000598
- 60 SLE classification criteria: Science-based icons or algorithmic distractions in an intellectually demanding dilemma. 13,
- 59 Egyptian evidence-based consensus on clinical practice recommendations for the management of lupus nephritis. **2022**, 49,
- 58 The first-year course of urine MCP-1 and its association with response to treatment and long-term kidney prognosis in lupus nephritis.

- 57 The pathological spectrum of pediatric kidney disease: 18-Year experience from a single tertiary care center in northern Taiwan. **2022**, 0
- 56 Sleep impairments and quality of life in Thai adolescents with systemic lupus erythematosus. **2022**, 1
- 55 The long-term outcome of New Zealand Maori and Pacific Island children diagnosed with childhood onset lupus nephritis. 096120332211284 0
- 54 Serum beta-2 microglobulin as a predictor of nephritis, disease activity, and damage score in systemic lupus erythematosus: a cross-sectional study. 0
- 53 Cutaneous vasculitis occurring in the setting of systemic lupus erythematosus: a multicenter cohort study. 0
- 52 The Behaviour of Serum Survivin in Patients With Lupus Nephritis. **2022**, 17, 117727192211314 0
- 51 Systemischer Lupus erythematosus und Lupusnephritis: neue Therapiestrategien. **2022**, 26, 352-358 0
- 50 Tertiary lymphoid tissues in kidney diseases: a perspective for the pediatric nephrologist. 0
- 49 The Outcome of Kidney Transplantation in Lupus Patients. 0
- 48 Induction therapy for pediatric onset class IV lupus nephritis: Mycophenolate Mofetil versus Cyclophosphamide. 0
- 47 Long-term outcomes of children and adolescents with biopsy-proven childhood-onset lupus nephritis. **2022**, 0
- 46 Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. 0
- 45 Documento de consenso del Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN) para el diagnóstico y tratamiento de la nefritis lúpica. **2022**, 0
- 44 The influence of repeated flares in response to therapy and prognosis in lupus nephritis. 0
- 43 Diagnostic des arthrites d'origine auto-immune. **2022**, 2022, 45-55 0
- 42 A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejection.. **2022**, 0
- 41 Performance optimization of water cycle algorithm for multilevel lupus nephritis image segmentation. **2023**, 80, 104139 0
- 40 Lupus Nephritis. **2022**, 400-424 0

- 39 Lupus Nephritis and Lupus Podocytopathy. **2022**, 105-154 ○
- 38 Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII. **2022**, 135, 2191-2199 1
- 37 Lupus nephritis: Is it necessary to systematically repeat kidney biopsy?. **2022**, ○
- 36 Validity of immunoglobulin-binding protein 1 as a biomarker for lupus nephritis. 096120332211412 ○
- 35 Chronic kidney disease in patients with childhood-onset systemic lupus erythematosus. ○
- 34 Dysentery and leg ulcer as an atypical presentation of systemic lupus erythematosus: A case report. **2022**, 101, e32201 1
- 33 Renal Tissue Expression of BAFF and BAFF Receptors Is Associated with Proliferative Lupus Nephritis. **2023**, 12, 71 ○
- 32 Unraveling the Link between Interferon- β and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies. **2022**, 23, 15998 ○
- 31 A spatially guided machine learning method to classify and quantify glomerular patterns of injury in histology images. ○
- 30 Lupus nephritis as a specific clinical and immunological phenotype of systemic lupus erythematosus. **2022**, 16, 12-19 ○
- 29 Urine Galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus. 096120332211455○
- 28 Searching for a prognostic index in lupus nephritis. **2023**, 28, ○
- 27 Pulmonary renal syndrome: a clinical review. **2022**, 18, 220208 ○
- 26 Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function. **2022**, 9, e000773 ○
- 25 Urine biomarker score captures response to induction therapy with lupus nephritis. ○
- 24 Case report: disease mechanisms and medical management of calcium nephrolithiasis in rheumatologic diseases. **2023**, 23, ○
- 23 Clinicopathologic features in childhood-onset lupus nephritis with antineutrophil cytoplasmic antibody positivity: a multi-center retrospective study. 096120332311712 ○
- 22 National guidelines for the management of lupus nephritis in Saudi Arabia. **2022**, 2, 35 ○

- 21 Noninvasive Evaluation of Lupus Nephritis Activity Using a Radiomics Machine Learning Model Based on Ultrasound. Volume 16, 433-441
- 20 Anti-dsDNA B-Cell ELISpot as a Monitoring and Flare Prediction Tool in SLE Patients. **2023**, 12, 1295
- 19 Lupusnephritis Von der Diagnose zur Therapie.
- 18 The Role of New 3D Pathology and Lymphocyte Expression of Interstitial Inflammation in Pediatric-Onset Lupus Nephritis. **2023**, 24, 3512
- 17 Complement as a Biomarker for Systemic Lupus Erythematosus. **2023**, 13, 367
- 16 Identification of biomarkers that predict renal flare in childhood-onset lupus nephritis with mycophenolate acid. **2023**, 117, 109900
- 15 Similarity and difference between systemic lupus erythematosus and NZB/W F1 mice by multi-omics analysis.
- 14 Significance of co-positivity for anti-dsDNA, -nucleosome, and -histone antibodies in patients with lupus nephritis. **2023**, 55, 1009-1017
- 13 Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement. 096120332311646
- 12 Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients. **2023**, 45,
- 11 Glomerular Clinicopathologic Syndromes. **2018**, 162-174
- 10 The value of 2019 EULAR/ACR classification criteria in predicting lupus nephritis in childhood-onset systemic lupus erythematosus.
- 9 The 2010 Nephrology Quiz and Questionnaire. **2011**, 6, 2534-2547
- 8 Secondary Glomerular Disease and Renal Vasculitis. **2023**, 213-227
- 7 Updates in renal pathology. **2023**, 42, 153-154
- 6 Prevalence of lupus nephritis and the use of serology in a central South African chronic kidney disease patient cohort.
- 5 Lupus Nephritis. **2023**, 737-763
- 4 Tools for Kidney Tissue Analysis. **2023**, 171-185

- 3 Increased Immunoglobulin Gamma-3 Chain C in the Serum, Saliva, and Urine of Patients with Systemic Lupus Erythematosus. **2023**, 24, 6927 ○
- 2 GuillainBarre syndrome as the initial presentation of systemic lupus erythematosus: Case report with a systematic and literature review. **2023**, ○
- 1 Update on scoring and providing evidence basis for assessing pathology in lupus nephritis. **2023**, 103, 813-816 ○